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Oxidative stress resulting from an imbalance between free radicals and antioxidants is 
considered to be an important etiological factor in the development and maintenance of 
hypertension. Angiotensin II (Ang II) has been shown to be an important regulator of blood 
pressure and acts to elevate blood pressure by its pressor effects. The pressor effects of Ang 
II are well documented but recent evidence has suggested another possible role of Ang II in 
elevating blood pressure, whereby it acts via an independent mechanism that is directly 
linked with oxidative stress. 
The spontaneously hypertensive rat (SHR) is a widely used model in the investigation of the 
pathophysiological mechanisms involved in hypertension. This study was therefore 
undertaken to determine whether Ang II acts as a causative factor via oxidative stress in the 
development and maintenance of hypertension in the SHR. This was elucidated by evaluating 
the role of both the endogenous in vivo levels of Ang II as well as an exogenous sub-pressor 
dose of Ang II, on oxidative stress and its associated parameters. The parameters evaluated 
included, the antioxidant status of the model on the basis of the levels of the major 
antioxidant enzymes viz. SOD, GPx and catalase; the free radical generating capacity, by 
assessing the activity of the membrane bound enzyme NADPH oxidase and the levels of 
H2O2. The study also evaluated the levels of the endogenous vasodilator nitric oxide (NO), 
remodelling of the vasculature and the level of tissue oxidative stress in the kidney.  
The results show that the SHR has an elevated plasma Ang II level and an elevated level of 
oxidative stress, thus showing that in this model there is an intimate link between oxidative 
stress and Ang II. The SHR also shows depleted levels of NO and thus a decreased 
vasodilatory capacity and increased remodelling of the vasculature. The kidney showed an 
increased level of lipid peroxidation, which was due to the elevated levels of oxidative stress. 
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All of these pathophysiological changes contribute to the elevation in blood pressure in this 
model. 
The long term infusion of the sub-pressor dose of Ang II affected the SHR to a greater extent 
than the Wistar. Although the dose of Ang II elevated the blood pressure in both models, the 
degree of the pathophysiological changes associated with the elevation in blood pressure was 
greater in the SHR. The Ang II infusion in both these models demonstrated that in the SHR 
which is genetically predisposed to hypertension, adjustments are made to the antioxidant 
system, that result in an elevated level of protection against oxidative stress. 
These results show that Ang II acts as a causative factor in the pathogenesis of hypertension 
in the SHR via its well documented pressor effects, as well as via a multitude of independent 
mechanisms that are linked to oxidative stress. This is substantiated by the significant 
decrease in NO that is caused by the elevated oxidative stress, as well as the previously 
described pathophysiological changes. This study has therefore shown that Ang II has an 
intimate causative link with oxidative stress that results in parallel mechanisms that work 





Free radical generation in an organism occurs as a result of the organisms normal metabolic 
processes. Under physiological conditions, free radical mediated derangements are prevented 
by antioxidants. When excessive free radical formation occurs in the body and/or there are 
compromised levels of antioxidants i.e. the pro-oxidants overwhelm the antioxidants, the 
resulting situation is referred to as oxidative stress. Thus oxidative stress is a general term 
used to describe a state of potential damage caused by free radicals. This state of potential 
free radical mediated damage has been intimately linked with various disease states including 
hypertension (Sies., 1997; Halliwell and Gutteridge., 1999). 
It is well known that Angiotensin II (Ang II) plays an important role in blood pressure 
regulation. The actions of Ang II are fairly widespread, and Ang II acts on the blood pressure 
regulating organs/tissues to bring about an elevation in blood pressure. 
There also exists substantial experimental evidence indicating that reactive oxygen species 
(ROS) play an important pathophysiological role in the development and maintenance of 
hypertension, this being due to a relative increase in the production of the superoxide radical 
(O2-) and hydrogen peroxide (H2O2) in hypertension. The O2- radical has been shown to 
scavenge nitric oxide and reduce its bioavailability, thus reducing its vasodilatory role on the 
vasculature (McIntyre et al., 1999). The relative increase of both O2- and H2O2 with resultant 
tissue oxidative stress has also been shown to decrease the natriuretic and diuretic properties 
of the kidney, thus reducing the organs ability to lower blood pressure (Meng et al., 2003). 
Both these species have also been shown to promote vascular smooth muscle cell (VSMC) 
growth, and contribute to the blood pressure amplifier consequence of vascular remodelling 
(Touyz., 2003; Taniyama and Griendling., 2003; Touyz., 2004; Paravicini and Touyz., 2008). 
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Compelling experimental evidence suggests that both the Ang II and the oxidative stress 
mechanisms are intimately linked. Ang II has been shown to stimulate the production of free 
radicals in the vasculature of rats, via the activation of the membrane bound enzyme NADPH 
oxidase (Griendling et al., 1994; Rajagopalan et al., 1996). Thus this study will attempt to 
investigate whether the activation of this membrane bound enzyme (NADPH oxidase) by 
Ang II initiates the production of free radicals and results in a state of elevated oxidative 
stress. A state of elevated oxidative stress and its deleterious derangements have been 
previously shown in part, to be responsible for an elevation of blood pressure in hypertension 
(de Champlain et al., 2004). 
The spontaneously hypertensive rat (SHR) has proven to be an excellent model to investigate 
the pathophysiological changes that occur in hypertension. Thus this study will investigate 
the role of Ang II in this model of genetic hypertension, and elucidate whether Ang II 
elevates the blood pressure by stimulating the production of free radicals and thus inducing a 
state of oxidative stress. The study will also aim to answer whether the elevation in blood 
pressure evident in this model arises as a consequence of oxidative stress, or whether the 
oxidative stress is a consequence of the elevation in blood pressure. 
Furthermore, the study will aim to investigate the role of oxidative stress as a possible 
mechanism by which a long term sub-pressor dose of Ang II (i.e. a dose of Ang II that has 
been shown to not elicit immediate pressor effects in the kidney and in the vasculature, but 
elevates blood pressure over the long term) is able to elevate the blood pressure of 
normotensive rats (Simon et al., 1995). This would allow the study to show whether there 
exists other mechanisms by which Ang II is capable of increasing the blood pressure, and 
investigate whether oxidative stress is one of these mechanisms. 
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The study will also subject the SHR to a long term sub-pressor dose of Ang II, and 
investigate whether this dose will exacerbate the onset and level of hypertension in this 
model, and determine the role, if any that is played by oxidative stress. This would allow the 
study to compare and contrast the response of the free radical and antioxidant systems of both 
the genetically normotensive model (i.e. Wistar), and the genetically hypertensive model (i.e. 
SHR) to the sub-pressor dose of Ang II. 
The evidence that this study will provide, will allow for the development of strategies to 
strengthen the use of antioxidant therapies that are co-administered with Ang II converting 
enzyme (ACE) inhibitors and Ang II antagonists (AT-1 blockers) in the treatment and 
management of hypertension. This would also allow for the use of these therapies as both 
preventative and management treatments for hypertension. It is also hoped that this research 













2. LITERATURE REVIEW 
2.1 HYPERTENSION 
2.1.1. Definition 
Blood pressure has previously been described as a quantitative trait that is highly variable 
(Parati et al., 1998). However, with a persistent elevation in the level of blood pressure, there 
is a positive correlation with an increased risk for associated organ damage, especially 
cardiovascular diseases such as stroke, myocardial infarction and heart failure as well as renal 
disease (Carretero and Oparil., 2000). Hypertension can therefore be stated to be the elevated 
level of blood pressure that is associated with an increase in morbidity and mortality.  
Since, more general clinical definitions show that hypertension, is that level of blood pressure 
at which detection and treatment will do more good than harm to an individual’s health, it can 
be defined as both a risk factor as well as a pathological condition, and therefore offers a new 
challenge in the management of this condition (WHO Guidelines., 2003). 
Hypertension, is characterized by the World Health Organization (WHO) as a systolic blood 
pressure (SBP) of 140 mmHg or greater and a diastolic blood pressure of 90 mmHg or 
greater. Table 1 shows a classification system by WHO to rank blood pressure into different 
grades, linked with patient history and predisposing risk factors, and classifies patient risk 
(WHO Guidelines., 2003). This classification allows for the individual patient dependant 







Table 1: Classification and Stratification of risk to quantify prognosis of Hypertension (WHO 
Guidelines., 2003) 
Other risk Factors 
and 
Disease History 
BLOOD PRESSURE (mmHg) 
GRADE 1 
(SBP 140-159 or 
DBP 90-99) 
GRADE 2  
(SBP 160-179 or  
DBP 100-109) 
GRADE 3  
(SBP ≥ 180 or  
DBP ≥ 110) 
 


















3 or more risk 
factors, 








SBP – Systolic blood pressure  
DBP – Diastolic blood pressure  
TOD – Target organ damage 
ACC – Associated clinical conditions e.g. left ventricular hypertrophy, chronic kidney disease, 
diabetic nephropathy, heart failure and cerebrovascular disease 








2.1.2. Types and Causes 
Classically hypertension has been divided into 2 types/classes viz: 
i) Essential/Primary/Idiopathic Hypertension and 
ii) Secondary Hypertension  
2.1.2.1. Essential Hypertension 
Essential hypertension is also referred to as primary or idiopathic hypertension and according 
to the many studies on the classification of hypertension this class/type of hypertension 
accounts for 90-95% of all hypertensive cases. Messerli et al., (2007), defined essential 
hypertension as, “a rise in blood pressure of unknown cause that increases the risk for 
cerebral, cardiac and renal events”. It is postulated that this type of hypertension does not 
have a single cause, but rather, in most cases, it is a combination of several etiological factors 
such as diet, lack of exercise, stress, metabolic effects, obesity and heredity thus manifesting 
as a disease condition with multifactorial origins. 
2.1.2.2. Secondary hypertension 
The remaining 5-10% of hypertension cases is termed secondary hypertension, which results 
as a consequence of other known or identifiable diseases/medical states such as renal disease, 







2.1.3. The Role of Heredity in Essential Hypertension  
The two phenotypes that determine blood pressure viz. total peripheral resistance and cardiac 
output are further controlled by intermediate phenotypes which include vasopressor/depressor 
hormones, the structure of the cardiovascular system, the autonomic nervous system, body 
fluid volume and renal function amongst others. This fact thus complicates the identification 
of variant genes that contribute to the development of hypertension (Carretero and Oparil., 
2000). 
Although it is not known exactly which genes cause a variation in genetically determined 
blood pressure, from the many familial studies, it has been shown that genetically determined 
blood pressure can range from a low normal to severe hypertension (Carretero and Oparil., 
2000). 
Recent studies have shown that blood pressure can be either raised (from a normal blood 
pressure) or lowered (from high blood pressure) through a common pathway that involves 
increasing or decreasing salt and water absorption respectively, by the nephron, and this can 
arise due to mutations in at least 10 variant genes (Lifton., 1995; Lifton., 1996; Carretero and 
Oparil., 2000). 
The literature shows that the causative role that heredity plays via genetic variations (this 
includes most blood pressure regulating factors) in essential hypertension is a very important 
one (Luft., 1998). When this genetic susceptibility is combined with the environmental or 
metabolic factors stated previously, this leads to essential hypertension becoming a 
deleterious syndrome that affects a fairly large percentage of the population. 




2.2. FREE RADICALS 
An atom is most stable in the ground state. In order for the atom to be in this ground state 
every electron in the outermost shell must have a complimentary electron that spins in the 
opposite direction, and thus the atom is considered to be "ground". If an atom has at least one 
unpaired electron in the outermost shell, this species is referred to as a free radical; 
importantly this resultant species is capable of independent existence. Free radicals thus 
become highly reactive due to the presence of these unpaired electron(s) (Karlsson., 1997). In 
addition when free radicals donate an electron to, or accept an electron from a surrounding 
compound or molecule, that compound or molecule becomes a free radical itself. Biologically 
this process initiates a self-perpetuating chain reaction that ultimately results in a disturbance 
in both intracellular and extracellular homeostatic balance and eventual cellular damage 
(Halliwell., 1994). 
2.2.1. Reactive Oxygen Species  
A free radical  that is derived from oxygen is referred to as a reactive oxygen species (ROS). 
Molecular oxygen in the ground state is a bi-radical, which means that it contains two 
unpaired electrons in the outer shell, and this is also known as the triplet state. The two single 
(i.e. the unpaired) electrons have the same spin, resulting in the oxygen molecule only being 
able to react with one electron at a time. Therefore the oxygen molecule is not very reactive 
when the two electrons are in a chemical bond. However, if one of the two unpaired electrons 
reaches an excited state and changes the direction of its spin, the resulting species which is 
now called a singlet oxygen, becomes a powerful oxidant. This is due to the two electrons 
having an opposing spin, and can thus quickly react with other electron pairs. This is 
especially so for double bonds. The one electron reduction of molecular oxygen produces 
relatively stable intermediates. The superoxide anion (O2-), is one such product, and is the 
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precursor of most ROS and is also a mediator in oxidative chain reactions. Dismutation of O2- 
(either spontaneously or through a reaction catalysed by superoxide dismutase - SOD) 
produces hydrogen peroxide (H2O2), which in turn may be fully reduced to water or partially 
reduced to the hydroxyl radical (OH-), one of the strongest oxidants in nature (Reaction series 
shown below) (Turrens., 2003). 
O2  +  e -  →  O2-   - Superoxide Radical  (1) 
O2  +  H2O  →  HO2. + OH-  - Hydroperoxyl radical (2) 
HO2  +  e - + H  →  H2O2  - Hydrogen Peroxide  (3) 
The superoxide (O2 -) and hydroxyl (OH -) radicals are examples of reactive oxygen species. 
However, the term reactive oxygen species can also refer to oxygen-derived non-radicals 
such as H2O2, ozone (O3), hypochlorus acid (HOCl) and the singlet oxygen (1O2). Nitric 
oxide (NO -) and nitrogen dioxide (NO2 -) are nitrogen radicals, but the term ROS also 
encompasses certain non-radicals such as nitrous acid (HNO2) and peroxynitrite (ONOO -) 
Table 2. (Halliwell et al., 1992).  
Table 2. Reactive Oxygen Species 



























 R = lipid 
Biologically ROS are found in several cells including macrophages, vascular smooth muscle 
cells (VSMC) and endothelial cells (EC). At low concentrations these ROS can act as 
physiological mediators of cellular responses such as signal transduction, cell growth and 
inflammation. However at higher concentrations ROS may cause cell damage and death due 
to its indiscriminate targeting of proteins, lipids, polysaccharides and DNA (Irani., 2000). 
Biologically the “leakages” from the electron transport chains of mitochondria and 
endoplasmic reticulum are the major sources of ROS. Only 1–2% of these electrons are 
“leaked” to generate superoxide radicals in reactions mediated by coenzyme Q and 
ubiquinone and its complexes. Neutrophils and macrophages produce reactive oxygen species 
during phagocytosis (‘oxygen burst’) or stimulation with several agents through the activation 
of nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase that is assembled at the 
plasma membrane from resident plasma membrane components and cytosolic protein 
components (Forman and Torres., 2002). NADPH oxidase is also, a major source of vascular 






2.2.2. Implications of Free radicals in the Disease State 
Pathological conditions such as cancer, inflammation and hypertension may develop in cases 
of persistently elevated ROS levels. Pathological conditions result in a change in homeostatic 
balance. Accordingly, pathological symptoms may result from both ROS-mediated changes 
in gene expression and/or the damaging effects of ROS on the integrity of the tissue (Droge., 
2002).      
Free radicals are very reactive species that damage biologically critical molecules (Halliwell 
et al., 1992). ROS react directly with cellular lipids, proteins, and DNA, causing cell damage, 
leading to cell death. Direct DNA damage is usually caused by free radicals in close 
proximity, whereas indirect damage for example, can be caused by free radicals impairing 
production of the proteins that are needed to repair DNA (Dhalla et al., 2000; McGee et al., 
2003). Alteration in DNA has been shown to be a major factor in the development of cancer. 
Free radicals have been shown to attack fatty acid side chains of intracellular membranes and 
lipoproteins, this self-perpetuating attack causes a chain reaction known as lipid peroxidation. 
The by-products of lipid peroxidation cause further damage to membrane proteins, by making 
the cell membrane “ leaky” and eventually leading to loss of membrane integrity. The last 
structures damaged by free radicals are cellular proteins. Oxidized proteins may trigger 
antibody formation, autoimmune processes and can cause inactivation of critical enzymes 
that induce denaturation thereby rendering proteins non-functional (Halliwell and 
Gutteridge., 1999). 
The literature thus shows that, damage due to free radicals is intimately linked with many 
disease states. The causes of the increase in free radical production in the different disease 




2.3.  ANTIOXIDANTS 
2.3.1. Definition 
All organisms that respire aerobically have evolved defense mechanisms against free radicals 
and these agents are collectively known as antioxidants. A concise definition of an 
antioxidant was provided by Halliwell and Gutteridge, (1989), who defined an antioxidant as 
“any substance that, when present at low concentrations compared with that of an oxidizable 
substrate, significantly delays or inhibits oxidation of that substrate.” This definition would 
include antioxidants of both an enzymatic and non-enzymatic origin (Sies., 1997). 
2.3.2. Types/Classes 
Thus due to their origin, antioxidants can be broken up broadly into 2 types/classes viz.; 
i) Enzymatic antioxidants and 
ii) Non-enzymatic antioxidants  
2.3.2.1. Enzymatic antioxidants (Intracellular/Endogenous Antioxidants) 
There are 3 major classes/types of enzymatic antioxidants (antioxidants enzymes) viz; 
1. The Superoxide Dismutases (EC 1.15.1.1) 
2. The Glutathione Peroxidases (EC 1.11.1.9) 






2.3.2.1.1. The Superoxide Dismutases  
The superoxide dismutases (SOD) are the major cellular defense against the superoxide 
radical (O2-). They convert (dismutate) O2- to hydrogen peroxide (H2O2)  via the following 
reaction: 
2O2.- + 2H- → H2O2 + O2 
These enzymes contain redox metals such as copper (Cu), zinc (Zn) and manganese (Mn) in 
their catalytic centre and are found in the mitochondria and the cytosol (Halliwell., 1996).  
There exists 3 different isoforms of SOD, firstly the mitochondrial Mn-containing SOD 
(MnSOD, SOD-2), then the cytosolic Cu/Zn containing SOD (Cu/Zn-SOD, SOD-1) and the 
extracellular SOD (ecSOD, SOD-3), which is also a Cu/Zn containing enzyme that is 
produced and secreted mainly by vascular smooth muscle cells (VSMC’s) (Wassmann et al., 
2004).  
SOD-1 is located in the cytosol and nucleus of all cell types. Whereas the SOD iso-enzymes 
are normally thought to be protective, it is postulated that increased SOD-1 activity produces 
increased amounts of H2O2, which become toxic in the presence of normal glutathione and 
catalase activity (Yarom et al., 1988). 
SOD-2 is synthesized in the cytoplasm and directed to the mitochondria by a signal peptide, 
where it is involved in dismutating the O2- generated by the respiratory chain of enzymes. The 
essential role of SOD-2 is to maintain mitochondrial function and prevent an accumulation of 
O2- in the organelle (Li et al., 1995). 
SOD-3 is produced in fibroblasts and glial cells and secreted into the extracellular fluid, where 
it is the principal SOD. SOD-3 exists in the vasculature mainly bound to the surface of the 
endothelial cells and the extracellular matrix. Because of its location, SOD-3 has been 
identified as the principal regulator of endothelium-derived nitric oxide (NO) bioavailability, 
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although this does not exclude cytosolic SOD-1 which is also thought to be an important 
regulator (Marklund et al., 1982; Oury et al., 1996; McIntyre et al., 1999). 
2.3.2.1.1.1. Cu/Zn SOD (SOD-1) Expression 
Cu/Zn SOD has been shown to have a fairly widespread distribution, in many different cell 
types (Crapo et al., 1992). The expression of the cytoplasmic Cu/Zn SOD has been shown to 
be stable and its relative activity is often adopted as an internal control for Cu/Zn SOD gene 
expression (Zelko et al., 2002). 
The Cu/Zn SOD mRNA levels have been shown to be regulated by various physiological and 
pathological conditions. An elevation of Cu/Zn SOD mRNA levels has been shown in 
response to many different conditions such as elevated hydrogen peroxide (Yoo et al., 
1999a), arachidonic acid (Yoo et al., 1999b), and depressed nitric oxide levels amongst 
others (Frank et al., 2000; Zelko et al., 2002). 
A down regulation of Cu/Zn SOD has been shown in experimental animals exposed to 
hypoxic environments (Jackson et al., 1996). 
As can be seen, the changes in expression of Cu/Zn SOD in many pathological conditions are 
adaptive to conditions that promote free radical formation. These adaptive changes act to 











2.3.2.1.2 The Glutathione Peroxidases 
The glutathione peroxidases (GPx) are widely distributed in animal tissues. They are 
essentially a selenium-containing antioxidant enzyme that efficiently reduces hydrogen 
peroxide and lipid peroxides to water and lipid alcohols, respectively. Within this process the 
glutathione is in turn oxidized to glutathione disulfide (Wassmann et al., 2004). 
Selenium is vital for the activity of these tetrameric enzymes. Dietary selenium actively 
participates in the catalytic reaction, and this is often the basis for antioxidant protection 
offered by supplemental selenium. Selenium-containing peroxidases comprise a family of 
enzymes of at least four types. The "classic" glutathione peroxidase acts on H2O2 and 
hydroperoxides of fatty acids and cholesterol, but not esterified lipids such as those present in 
lipoproteins. Phospholipid hydroperoxide glutathione peroxidase (PHGPx) is the only enzyme 
known to reduce complex lipid hydroperoxides in lipoproteins (Stocker and Keaney., 2004). 
Inadequate glutathione levels, or the absence of GPx activity, would result in hydrogen 
peroxide and lipid peroxide accumulation, and these substances may then be converted to 
hydroxyl radicals and lipid peroxyl radicals, respectively, by transition metals (e.g., Fe2+and  
Cu2+). By detoxifying and thus preventing the accumulation of H2O2 and the lipid peroxyl 
radicals, the GPx/glutathione system is thought to be a major defense in low-level oxidative 
stress (Wassmann et al., 2004). 
Reduced glutathione (GSH) is said to be one of the most important enzymatic oxidant 
defenses within the body. It is found in very large quantities (mM levels) within cells where it 
acts to detoxify peroxides as well as maintain other physiologically important antioxidants in 
their reduced form (Tarpey et al., 2004). Jones., (2002), has suggested that, “the balance of 
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GSH and GSSG provides a dynamic indicator of oxidative stress in vivo”. In vivo levels of 


















2.3.2.1.3. The Catalases 
The catalases are responsible with glutathione for decomposing H2O2 to H2O and O2. The 
catalases are located in peroxisomes and to some extent in the cytosol. The catalases are 
widely distributed in the human body, with high concentrations been shown in the liver, 
kidney and erythrocytes (Reimer et al., 1994; Nishikawa et al., 2009).  
A single molecule of catalase (CAT) has been shown to have the potential to breakdown 40 
million molecules of H2O2 per second. The process of CAT decomposing H2O2 indirectly 
detoxifies O2- radicals, because the dismutation of the superoxide radical by SOD produces 
H2O2 as an end product (Wassmann et al., 2004). 
The enzyme has also been shown to have peroxidase activity and thus reacts with organic 
peroxides and H+ donors, and breaks them down to H2O and organic alcohols. These 
peroxidatic reactions have been shown to be present at low levels of H2O2, but the catalatic 
reaction predominates at higher H2O2 concentrations. The main difference in the catalatic and 
peroxidatic reactions, can be attributed to their reaction rates, where the catalatic reaction rate 
has been shown to be one of the fastest known enzymatic reaction rates, and the peroxidatic 
rate is relatively slow (Kirkman and Gaetani., 2006). Thus this shows that catalase is more 
efficient during states where H2O2 levels are higher than when there are lower H2O2 levels.  
Therefore during states of high-level oxidative stress (when H2O2 levels are high), catalase 
will be the primary defense to protect cells from the endogenously produced H2O2. Thus 
catalase would be very important during cases of limited glutathione levels/decreased GPx 
activity and would play an important role in the development of tolerance to oxidative stress 
(Cai., 2005; Kirkman and Gaetani., 2006; Paravicini and Touyz., 2008).  
18 
 
CAT deficiency has been categorized into 2 types, firstly when there is less than 10% of 
normal CAT activity, this is known as acatalasemia, and when there is ~50% of normal 
catalase activity this is categorized as hypocatalasemia  (Goth and Eaton., 2000). These 
conditions usually result in a dysregulation of H2O2, and H2O2 accumulation , which has been 
shown to result in hydrogen peroxide-induced lipid peroxidation and it has also been shown 
to induce vascular remodeling, amongst other pathologies (Hyoudou et al., 2006; Nishikawa 















2.3.2.2. Non-enzymatic Antioxidants  
As shown in Table 3, many substances of non-enzymatic origin can act as antioxidants, of 
these, the main non-enzymatic antioxidants are α-tocopherol, Vitamin C, the cartenoids and 
the flavenoids. 
Table 3: Classification of Antioxidants 
Primary Antioxidants 
Endogenous Antioxidants Dietary Antioxidants Metal Binding Proteins 
NADPH and NADH 
Glutathione and thiols (-SH) 




Vitamin C (Ascorbic acid) 








Vitamin E is the most important and researched α-tocopherol and is found in membranes and 
lipoproteins. It has been shown to inhibit the chain reaction of lipid peroxidation by 
scavenging intermediate peroxyl radicals, and has been shown to be extremely important for 






2.3.3. The Antioxidant System as a Unit of Defence 
The antioxidant system is essentially responsible for the protection of cellular components 
against oxidative damage. This system has been shown to be as diversified as the free radicals 
themselves. Although in previous descriptions the role of antioxidants has been discussed in 
isolation, this is however not how they function in vivo (Yu., 1994; Arora et al., 2003). 
The antioxidant system, although having individual components which at times have specific 
targets, the system and its components actually work together in a synergistic manner as a 
functional unit to quench the free radical threat and thus prevent/minimize the deleterious 
effects of oxidative stress. Yu., (1994), best described the integrated nature of the antioxidant 
system with the following statement; “In addition to the integration of intracellular cytosolic 
defenses, the cooperative interaction between the various antioxidants is crucial for maximum 
suppression of free radical reactions in extracellular compartments.”  
Although antioxidants are specific to the respective free radicals, the antioxidants display a 
“concert effect” pertaining to their free radical quenching actions. These actions are well 
coordinated and provide maximal protection against free radicals. An example to demonstrate 
the cooperative actions of the antioxidants is in the neutralizing of the superoxide radical. As 
discussed previously SOD neutralizes the superoxide radical by converting it to hydrogen 
peroxide. The resultant hydrogen peroxide, which is in itself a free radical, is then broken 
down by GPx and catalase, into H2O and O2, which are stable end products. If not for the 
coordinated actions of these antioxidants, then the self-perpetuating actions of the superoxide 
radical and hydrogen peroxide, would be deleterious to the organism. Thus, this example 
demonstrates the coordinated depth of the antioxidant system as a functional unit and shows 
how the antioxidants work in a synergistic manner with each other, to act against the diverse 
free radicals and thus manifest as a single functional unit of defense and protection. 
21 
 
2.4. THE RENIN ANGIOTENSIN SYSTEM  
The Renin Angiotensin System (RAS) has typically been seen as a hormonal circulating 
system that is solely involved in blood pressure regulation and Na+, K+ and fluid 
balance/homeostasis. The system responds to a drop in blood pressure, or changes to ionic 
concentrations of Na+/K+, and brings about its actions via Angiotensin II. The 
effects/mechanism of action of this system is best described by the following flow diagram: 
 
Figure 1: Renin Angiotensin System 
http://www.ourmed.org/images/a/a2/Renin-angiotensin-aldosterone_system.png 
Thus, it can be seen that the active component of the system is Angiotensin II, and it acts 







2.4.1. Angiotensin II 
Ang II is an octapeptide (8 amino acids) whose effects are fairly wide acting. It brings about 
its effects on the CNS, kidneys, heart, blood vessels and adrenal glands. (Table 4) 
 
Table 4: Target Organs and Effects of Angiotensin II 
TARGET ORGAN EFFECT 
Central Nervous 
System (CNS) 
Increases Vasopressin/ADH secretion 
Kidneys 
i. Decreases renal blood flow by vasoconstriction of the renal 
afferent arteriole or by augmentation of tubuloglomerular 
feedback 
ii. Increases tubular Na+ reabsorption by increased Na+-H+ 
exchange at the S1 segment of the proximal tubule 
iii. Increases K+ excretion 
Heart 
i. Causes pathological cardiac hypertrophy by stimulating 
myocyte hypertrophy, myocyte gene reprogramming, fibroblast 
proliferation and extracellular matrix protein accumulation.* 
ii. Increased sympathetic nerve activity induced heart rate and 
contractility. 
Blood Vessels 
i. Induces VSMC proliferation, with resultant vascular 
remodelling, characterised by increasing vascular media width, 
increasing media cross sectional area, and increasing 
media/lumen ratios. 
ii. Increased sympathetic nerve activity induced vasoconstriction. 
Adrenal Glands 
Stimulation of aldosterone biosynthesis in the adrenal 
glomerulosa.* 
*Sealy and Laragh., 1995 
Thus the localized role of Ang II and its systemic actions act to increase the blood pressure 
over both the short-term and the long term. The final product Ang II, can be further broken 
down to Ang III, Ang IV and Ang (1-7). Ang III has been shown to be centrally involved in 
the regulation of blood pressure. Ang IV has been shown to have vasodilatory, 
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antiproliferative and cognitive actions and Ang (1-7) has been shown to have vasorelaxant 
properties (Sernia., 2001). 
A study by Griendling et al., 1994, has revealed an additional probable mechanism in which 
Ang II acts to increase blood pressure. Ang II infusion has been shown to increase the activity 
of the enzyme NADPH oxidase and this enzyme is responsible for the generation of O2- by 
VSMC’s.  
The O2- produced by this process, as stated previously, will increase blood pressure by acting 
as a potent localised vasoconstrictor, and also, due to its high affinity for NO, will readily 
combine with NO and thus limits/prevents NO’s vasodilatory actions. Thus these actions of 
O2- will bring about an increase in blood pressure, by increasing peripheral resistance.  
Other studies that have used Ang II infusion to induce hypertension in normotensive rats, 
have shown that the vasculature of these animals (viz. the aorta), responds to the increased 
levels of circulating Ang II, by increasing its activity of NADPH oxidase. This seems to be a 
fairly specific effect of Ang II, as normotensive rats made to be hypertensive to a similar 
degree with an infusion of noradrenalin, showed no change in the activity of the same 









2.4.2. The Angiotensin II receptors 
There are 2 types of Angiotensin II receptors viz. Angiotensin II Type 1 (AT1) and 
Angiotensin II Type 2 (AT2). The distribution of these receptors vary in different tissues with 
the AT1 receptor being extensively distributed in adult tissues that include the vasculature, 
heart, kidney, adrenal gland, liver, brain and lung, and the AT2 receptor is distributed mainly 
in the developing foetal tissues and in adult tissues that include the uterus, ovary, heart and 
adrenal medulla (Suzuki et al., 1993; Kim and Iwao., 2000). 
In rats and mice there are further subtypes of the AT1 receptor viz. AT1a and AT1b subtypes. 
They have been shown to have a 94% homology with respect to their amino acid sequence 
and have similar tissue distribution and pharmacological properties (Kim and Iwao., 2000). 
The AT1 receptor mediates all the known functions of Ang II to elevate blood pressure, such 
as vasoconstriction, increased cardiac contractility, aldosterone release and, renal Na+ and 
H2O absorption (Timmermans et al., 1993; Kim and Iwao., 2000), as well as the previously 
mentioned increase in NADPH oxidase activity (Seshiah et al., 2002; Paravicini and Touyz., 
2008).  
This as well as the accumulating literature shows that Angiotensin II is mediated almost 
exclusively by the AT1 receptor in many cardiovascular and renal diseases. This evidence has 
been supported by the development of the many AT1 receptor antagonists (commonly known 
at AT1 blockers) in the successful clinical treatment of patients diagnosed with hypertension 
(Kim and Iwao., 2000). Thus the regulation of the activity of the AT1 receptors is an 





2.5. NADPH OXIDASE 
NADPH oxidase, as mentioned previously, is a common name given to a membrane bound 
enzyme NADPH cytrochrome P-450 oxidoreductase. It is assembled at the plasma membrane 
from resident plasma membrane components and cytosolic protein components (Forman and 
Torres., 2002). This multi-subunit enzyme catalyzes O2- production via the 1-electron 
reduction of O2 using NADPH/NADH (Paravicini and Touyz., 2008). 
NADPH oxidase is thought to be one of the main enzymatic sources of ROS in the vascular 
wall that have been found to play a putative role in hypertension. Other enzymes include 
nitric oxide synthase, xanthine oxidase and cyclooxygenase (Mohazzab et al., 1994; 
Griendling et al., 1994; Pagano et al., 1995; Jones et al., 1996; Zalba., 2001). 
The vascular NADPH oxidase enzyme consists of a cytochrome b558 membrane complex, 
which is composed of membrane bound p22phox and gp91phox (Nox 2) sub-units, both these 
sub-units have been shown to be expressed in EC’s and fibroblasts, and the p22phox sub-unit 
is expressed in VSMC’s. The enzyme also consists of 3 cytosolic components viz., p47phox, 
p67phox and rac. The p47 and rac are expressed in EC’s, fibroblasts and VSMC’s while the 
p67phox being only expressed in EC’s and fibroblasts (Zalba., 2001). 
Studies have shown that vascular NADPH oxidase can also be responsive to numerous 
factors amongst them are growth factors, cytokines, mechanical forces (e.g. shear stress) and 
G protein-coupled receptor agonists (Bayraktutan et al., 2000; Li and Shah., 2002; Lassegue 
and Clempus., 2003; Miller et al., 2006; Takeya and Sumimoto., 2006; Paravicini and 
Touyz., 2008). Ang II has been shown to be one of the most important and potent regulators 
of NADPH oxidase. Ang II carries this out via its AT-1 receptors (Seshiah et al., 2002; 
Paravicini and Touyz., 2008). 
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Thus any disturbance in the activity of this membrane bound enzyme caused by the factors 
mentioned previously would result in an increase in production of the deleterious ROS O2-, 



















2.6. OXIDATIVE STRESS 
Oxidative stress can be defined as the disruption of the equilibrium between the factors that 
promote free-radical formation and the antioxidant defense mechanisms that attempt to 
inhibit them (Halliwell et al., 1992). Turrens., (2003) stated that, “oxidative stress is an 
expression used to describe various deleterious processes resulting from an imbalance 
between the excessive formation of reactive oxygen species (ROS) and/or reactive nitrogen 
species (RNS) and limited antioxidant defences”.  
It is known that minute changes in the steady-state concentration of these oxidants may play 
an integral role in intracellular signalling. However, situations that cause an uncontrolled 
increase in the steady-state concentrations of these oxidants leads to free radical-mediated 
chain reactions which indiscriminately target cellular components (Droge., 2002; Turrens., 
2003). 
2.6.1. Physiological Implications of Oxidative Stress 
Oxidative stress occurs in most human diseases, however this does not imply that oxidative 
stress is the primary cause of, or is responsible for the pathogenesis of these diseases. The 
increase in free radicals may actually be secondary to the disease process (Halliwell and 
Gutteridge., 1999).   
The clinical conditions that oxidative stress was found to play a role in were listed in an 
excellent review by Droge., (2002). This list included malignant diseases, diabetes, 
atherosclerosis, hypertension, chronic inflammation, human immunodeficiency virus (HIV) 
infection, neurodegenerative diseases and sleep apnoea. These diseases have also been shown 
to fall into two major categories. The first category is made up of, diabetes mellitus and 
cancer, and these conditions commonly show a pro-oxidative shift, suggesting that skeletal 
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muscle mitochondria may be the major site of the elevated production of ROS. These 
conditions may therefore be referred to as "mitochondrial oxidative stress”. The second 
category may be referred to as "inflammatory oxidative stress conditions" because it is 
typically associated with an excessive stimulation of NADPH oxidase activity by cytokines or 
other factors/agents. In these cases, increased ROS levels or changes in intracellular 
glutathione levels are often associated with the pathological changes (Droge., 2002).  
Oxidative stress has also been implicated by numerous studies in neurodegenerative diseases 
such as Down ’s syndrome and Alzheimer ’s disease (Droge., 2002).  The available literature 
on these topics is specific, vast and well investigated. This shows that local uncontrolled 
production of ROS/RNS occurs in several diseases which indicate how deleterious these 














2.6.2. Free Radicals, Oxidative stress and the link to Hypertension  
The reactive oxygen species such as the superoxide radical (O2-), hydrogen peroxide (H2O2), 
and the hydroxyl radical (OH-), play a critical role in the pathogenesis of hypertension, as 
well as in other CVD’s such as atherosclerosis, stroke, myocardial infarction, diabetes and 
ischemia-reperfusion injury (Paravicini and Touyz., 2008).  
In hypertension ROS and the resulting oxidative stress play a dual role. On the one hand, they 
affect vascular resistance by inactivating NO, thereby promoting vasoconstriction and an 
elevation of peripheral hemodynamic resistance. On the other hand, they may serve as trigger 
mechanisms for lesion formation and organ damage (Swei et al., 1997; Haliwell and 
Gutteridge., 1999; Touyz., 2003). 
2.6.2.1. Nitric Oxide (NO) 
Essential hypertension in several animal models of hypertension, including genetic models 
such as the SHR, is associated with an increased peripheral vascular resistance 
(Schnackenberg et al., 1998). de Champlain et al., (2004),  stated that “the homeostatic 
modulation of blood pressure depends on the harmonious balance between the 
vasoconstrictive and vasodilatory mechanisms.”  
Nitric oxide (NO) is known to be one of the most powerful endogenous vasodilators. Due to 
this, there are theoretical reasons as to why reduced levels of NO production or diminished 
bioavailability would lead to vasoconstriction and thus an increased peripheral vascular 
resistance. NO has been found to regulate the tone of normal vessels and this includes 
resistance vessels. NO also causes renal vasodilatation which results in diuresis and 
natriuresis. These are actions that would tend to lower blood pressure. Therefore, an 
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attenuation of this mechanism could theoretically cause an elevation in blood pressure 
(McIntyre et al., 1999). 
Several studies suggest that the superoxide radical interacts with NO and thus limits its 
bioavailability. The affinity of NO for superoxide is so high that its reaction rate is limited 
only by diffusion. Because superoxide effectively degrades NO, the biological activity of NO 
may be determined by the availability of superoxide (Zalba et al., 2001; Schnackenberg., 
2002; Shimokawa and Matabo., 2004). 
During oxidative stress, NO depletion occurs due to the reaction of NO with the superoxide 
anion to form peroxynitrite (ONOO-). The presence of peroxynitrite in cells can lead to a 
number of adverse effects, including protein nitration, lipid peroxidation, DNA degradation 
and enhanced tubuloglomerular feedback responses (Hemnani and Parihar., 1998; Unlap et 
al., 2003). The reaction of O2- and NO is biologically significant because it reduces the 
vasodilatory capacity of the vessel (Rojas et al., 2006). O2- and OONO- have been shown to 
stimulate vascular smooth muscle cell growth and thus vascular remodelling, and these 
products also favour inflammation of the vasculature and platelet aggregation (Cai and 
Harrison., 2000; Zalba et al., 2001; de Champlain et al., 2004). 
The above mentioned studies provides convincing evidence that oxidative stress plays an 
important role in hypertension, in part by reducing the levels of NO. The most compelling 
evidence is provided by studies that have intravenously administrated SOD-Hb, an artificially 
synthesised form of SOD (a SOD mimetic), the SOD-Hb significantly decreased the blood 
pressure of the SHR (which had been shown to have elevated levels of O2-), but not of the 
Wistar controls (which had been shown to have lower levels of O2-), demonstrating the 
significant role played by the decreased bioavailability of NO due to O2- (Nakazono et al., 
1991). More recent studies using the SOD mimetic tempol have shown similar results, and 
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have thus provided evidence of the putative role played by NO, O2-, OONO- and the resultant 
oxidative stress in hypertension (Simonsen et al., 2009).  
2.6.2.2. Vascular Remodelling 
ROS production is closely involved with many of the processes that lead to both hypertrophic 
and proliferative vascular smooth muscle cell (VSMC) growth (Taniyama and Griendling., 
2003). ROS act as mediators in the proliferative response to agonists such as platelet-derived 
growth factor (PDGF) and thrombin (Berk., 2001). H2O2 has been shown to induce VSMC 
proliferation, although this effect is critically dependent on the concentration of H2O2 to 
which cells are exposed (Rao and Berk., 1992). Furthermore, VSMC proliferation by PDGF 
or thrombin requires H2O2 generation (Brown et al., 1999). Endogenously produced H2O2 
may also be important in modulating survival and proliferation of VSMCs. High 
physiological concentrations of H2O2 have also been found to induce apoptosis (programmed 
cell death), while moderate concentrations cause cell cycle arrest (Deshpande et al., 2002; 
Taniyama and Griendling., 2003). Intracellular H2O2 may also act as a second messenger for 
a variety of growth factors. For example, stimulation of VSMC’s by PDGF, epidermal 
growth factor, fibroblast growth factor and Ang II all lead to a rise in intracellular H2O2  
concentration. H2O2 does not function as a mitogen for VSMC, instead it is a stimulus to 
trigger VSMC apoptosis (Li et al., 1997). 
It has been shown previously that Ang II can induce VSMC hypertrophy. NADPH-driven 
superoxide production in cultured vascular smooth muscle cells and fibroblasts, is increased 
in the presence of Ang II, and this causes VSMC hypertrophy (Ushio-Fukai et al., 1999; 
Touyz et al., 2003). 
Dimmeler and Zeiher., (2000), have shown that exposure to O2- or endothelial injury and 
H2O2 induces apoptosis of EC’s, which leads to EC loss and results in atherogenesis and thus 
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a procoagulative state. ROS regulate apoptotic mechanisms induced by a variety of stimuli 
other that the ROS themselves (Taniyama and Griendling., 2003). Another type of 
programmed cell death, anoikis, results from detachment of ECs from the extracellular 
matrix. This process is associated with increased intracellular ROS, probably originating from 
mitochondria (Li et al., 1999). EC proliferation, migration and tube formation are crucial 
events that lead to apoptosis which essentially results in angiogenesis. ROS may be directly 
involved in all these mechanisms, as H2O2 has been shown to induce proliferation and 
migration of ECs and to mediate lymphocyte-activated tubulogenesis (Maulik and Das., 2002; 
Taniyama and Griendling., 2003). 
Structural vascular changes are the hallmark of chronic hypertension, and increased wall-to-
lumen ratio (W/L), of resistance vessels is the prominent lesion. Alterations in the structure of 
resistance vessels account for many of the features associated with essential hypertension 
(Mulvany., 1999). The increase in the relative “thickness” of resistance vessels is responsible 
for the “amplifier” property of the arterial circulation in hypertension, which functionally 
manifests itself as a pressor or vasoconstrictor hyper responsiveness (Simon et al., 1998). 
 
 
Figure 2: Classification of Vascular Remodelling (Mulvany., 1999) 
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The term “vascular remodelling” has been said to be used indiscriminately in the past to 
describe changes in the vasculature. The following proposal was put forward by Mulvany, 
(1999) in a review, it states: “... the term remodelling is to be used where there is a 
structurally determined change in lumen diameter, and that it be classified into the six 
changes indicated in Figure 2. It was suggested that remodelling should be termed inward or 
outward remodelling, depending on whether the process has resulted in a decrease or increase 
in diameter respectively. Furthermore, since remodelling can result in an increase, no change, 
or a decrease in the amount of material, that there should be a sub-classification into 
hypertrophic, eutrophic and hypotrophic remodelling, respectively”, as demonstrated in 
Figure 2. 
The author thus suggests that by adopting this uniform framework/classification for defining 
the various modes of vascular remodelling, it would become easier (for researchers) to 












2.6.2.3. Lipid peroxidation as an Indicator of Oxidative Stress 
Lipid peroxidation is a well-established mechanism of cellular injury in both plants and 
animals, that is mediated by free radicals, and is used as an indicator of oxidative stress in 
cells and tissues. It is a degenerative process that affects mainly cell membranes and other 
lipid-containing structures, during oxidative stress (Girroti., 1998; Arora et al., 2003). Lipid 
peroxides are unstable by nature and decompose to form a complex series of compounds 
including reactive carbonyl compounds. Polyunsaturated fatty acid peroxides generate 
malonyldialdehyde (MDA), 4-hydroxynonenal (4-HNE) and isoprostanes upon 
decomposition. Measurement of these decomposition end-products (MDA, 4-HNE and 
isoprostanes) has been used successfully as an indicator/measure of the level of in vivo lipid 
peroxidation (Esterbauer et al., 1991; Janika et al., 2010). 
Many of the methods used to detect lipid peroxidation in urine, blood plasma, or tissue are 
non-specific, relying on the detection of thiobarbituric acid reactive substances (TBARS), 
such as MDA or other reactive aldehydes generated in vivo or in vitro by the decomposition 
of lipid peroxidation products (Tarpey et  al., 2004). The literature shows that non-enzymatic, 
free radical-induced lipid peroxidation produces F2-like prostanoid derivatives of arachidonic 
acid, and these substances are called F2-isoprostanes. These F2-isoprostanes have been 
demonstrated to be a more reliable indicator of in vivo oxidative stress, because of their stable 
nature, and also because they can be measured in extracellular fluids such as urine and 
plasma. Because of this, it is now possible for a relatively non-invasive approach in assessing 
levels of in vivo oxidative stress (Roberts and Morrow., 2000; Tarpey et  al., 2004). 
Lipid peroxidation has been linked to a variety of disorders, including atherogenesis, diabetes, 
hypertension and UV-induced carcinogenesis (Girotti., 1998), and has been shown to be a 
deleterious consequence of the reported oxidative stress in these disorders.  
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2.6.2.3.1. Organ Damage due to Lipid Peroxidation 
The consequent peroxidation of membrane lipids caused by free radicals plays an important 
role in cell physiology and pathology (Wang and Salahudheen., 1995). The peroxidative 
degradation of polyunsaturated fatty acids has been found to produce changes in most of the 
membrane parameters, and the resultant disruption of the biological membranes results in 
alterations to the activity of the membrane bound enzymes (Pradhan et al., 1990). 
Decomposition of the polyunsaturated fatty acids of organelle membrane phospholipids by 
peroxides, would result in specific abnormalities of organelle function leading to cell injury 
or cell death (Popova and Popov., 2002). 
Hypertension has been shown to encourage significant structural and functional modifications 
in the kidney, that result in proteinuria, glomerular sclerosis, and other morphological 
changes, and it is these modifications that eventually lead to end-stage renal disease. A 
reduction in the blood pressure of hypertensive patients appears to hinder the progression of 
renal failure and also reduces the morbidity and mortality rates (Meng et al., 2003). 
Increased oxidative stress resulting in lipid peroxidation has been shown to contribute to both 
renal damage and impaired renal functioning. Studies that have infused isoprostanes into the 
kidney have been shown to induce renal vasoconstriction, thus decreasing glomerular 
filtration rate and thus natriuresis and diuresis (Morrow et al., 1992; Morrow et al., 1994; 
Reckelhoff et al., 2000). The aldehydes released during lipid peroxidation have been 
implicated as causative agents in cytotoxic processes, due to their self-perpetuating 
characteristics, in that when released from cell membranes they may diffuse, interact, and 
induce oxidative modifications in other cells (Redón et al. 2003). Apoptotic cell death has 
been shown to result in cell shrinkage, loss of plasma membrane asymmetry, protease and 
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endonuclease activation, and internucleosomal fragmentation of nuclear DNA. The apoptosis 
thereby resulting in an almost total loss to the integrity of the cells and tissue (Girotti., 1998). 
An increased level of lipid peroxidation is the evidence most frequently cited in support of 
the involvement of oxidative stress and damage in tissues (Liu et al., 2000). There is 
increasing evidence that oxidative stress contributes to organ damage by apoptosis and 
necrosis, in a multitude of disease states. The resulting organ damage is due to an increase in 
the peroxidation of membrane lipids in the presence of increased oxidative stress. Oxidative 
stress is an important aetiological factor in hypertension, which is accompanied by 
architectural changes in the kidney, heart and vessels that are often deleterious and can 
eventually contribute to end-organ disease such as renal failure, heart failure and coronary 













2.7. THE SPONTANEOUSLY HYPERTENSIVE RAT 
The spontaneously hypertensive rat (SHR) is one of the most widely used animal models for 
the study of essential hypertension. This model originated from the selective inbreeding of 
Wistar rats with an elevated blood pressure, which resulted in 100% of the progeny having 
naturally occurring hypertensive disease (Okamoto., 1963).  
The model develops a high blood pressure from the age of 5-6 weeks and the systolic blood 
pressure may reach values between 180-200 mmHg in the adult. There is a steady state 
increase in blood pressure as the animal ages. The SHR also has been shown to develop 
characteristics associated with cardiovascular disease, such as hypertrophy of the heart and 
blood vessels (Conrad., 1995).  
Studies have shown that the genetic basis for hypertension, is not yet fully understood. 
However this model has demonstrated a polygenic trait, with studies showing at least 3 major 
genes to be involved in early development, and an additional gene identified on chromosome 
10 has been shown to play a role in the development and maintenance of hypertension during 
aging in the SHR  (Ely and Turner., 1990; Yamori et al., 1999). More recent evidence 
suggests that the genetic mechanism of hypertension in the SHR, can be attributed to both 
vascular and neural alterations (Pinto et al., 1998; Lerman et al., 2005). 
Thus the characteristics of this widely used model, has proven over the years to be a reliable 








The flow diagram that follows, summarises the literature on the link between Ang II and 
oxidative stress, and the role of this link in contributing to an elevation in blood pressure. 
The factors/agents that are highlighted in red, are some of the parameters that were quantified 
by this study, and provide motivation and justification of the objectives of this study in light 
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3. MATERIALS AND METHODS 
3.1. ANIMAL PROTOCOL 
3.1.1. Ethical Approval and Standard Animal Protocol  
Ethical approval was obtained from the Animal Ethics Committee of the University of Kwa-
Zulu Natal (Reference Number: 015/08/Animal). 
Sixty two male rats were used in this study. The animals were acquired from the Biomedical 
Resource Unit at the University of Kwa-Zulu Natal – Westville Campus. The animals were of 
2 strains i.e. 31 Spontaneously Hypertensive Rats (SHR) rats and 31 normotensive Wistar 
control rats. These two groups were broken down further with no prejudice into the following 
groups (Table 5): 
Table 5. Animal Grouping   





SHR n = 8 n = 8 n = 7 n = 8 
Wistar n = 7 n = 8 n = 8 n = 8 
 
Animals were distinguished from each other by ear notching. All animals were housed in the 
Biomedical Resource Unit at the University of Kwa-Zulu Natal – Westville Campus, in 
standard rodent cages. Animals were fed standard Epol rat chow and deionised water 
(Millipore) was provided ad libitum.  
The room that the animals were housed in was maintained on a 12 hour light/dark cycle and 
maintained at a constant ambient temperature (230C) and pressure (101.3 kPa) for the 




The experiment commenced with all animals at weanlings (21 days old). Each of the groups 
in the table above (Table 5) had a different experimental protocol and duration. 
SHR–Normal and Wistar–Normal groups: 
Maintained for 28 days from weanling, at which point they were sacrificed. 
The SHR–Weanling and Wistar–Weanling groups: 
Sacrificed at 21 days old. 
The SHR–Angiotensin II Infused and Wistar–Angiotensin II Infused groups:  
Underwent minor surgery at weanling (21 days old) where they had a mini osmotic pump 
containing Angiotensin II subcutaneously inserted (as described in Section 3.2.1). These 
animals were then maintained for 28 days post surgery, after which they were sacrificed. It 
should be noted that the SHR – Ang II infused group, was sacrificed after 21 days of infusion 
(7 days earlier), due to the group’s health status, which was assessed by the in-house 
veterinarian. He found their health status to be unstable. Based on this assessment, the study 
was shortened, for this group. 
The SHR–Saline Infused and Wistar–Saline Infused groups:  
These groups also underwent the previously mentioned minor surgical procedure at weanling 
(21 days old), where they also had a mini osmotic pump inserted subcutaneously, however 
these pumps contained saline (0.9% NaCl), and were the sham operated control groups. 






3.1.3. ALZET™ OSMOTIC PUMP 
Angiotensin II delivery was achieved with the aid of an Alzet mini-osmotic pump (Durect 
Corporation) – Model 2004. This pump once surgically inserted into the animal delivers a set 
dose at a constant rate for 28 days. The 2004 model pump used for this experiment delivers 
the pre-determined dose at a rate of 0.25ul/hr for the 28 days. 
3.1.3.1. Background of ALZET™ Osmotic Pump 
ALZET™ osmotic pumps are miniature, implantable pumps that are widely used for research in 
mice, rats and other laboratory animals. These pumps can deliver pre-determined doses of drugs, 
hormones, and other test agents at a controlled rate.  
ALZET™ pumps operate because of an osmotic pressure difference between a compartment 
within the pump, called the salt sleeve, and the tissue environment in which the pump is 
implanted. The high osmolality of the salt sleeve causes water to flux into the pump through a 
semi-permeable membrane which forms the outer surface of the pump. As the water enters 
the salt sleeve, it compresses the flexible reservoir, displacing the test solution from the pump 
at a controlled, predetermined rate. Because the compressed reservoir cannot be refilled, the 
pumps are for single use only. The rate of delivery by an ALZET™ pump is controlled by the 
water permeability of the pump’s outer membrane. Thus, the delivery profile of the pump is 
independent of the drug formulation dispensed. Drugs of various molecular configurations, 
including ionized drugs and macromolecules, can be dispensed continuously in a variety of 
compatible vehicles at controlled rates. The molecular weight of a compound, or its physical 
and chemical properties, has no bearing on the rate of delivery by the ALZET™ pumps 





3.1.3.2. Surgical Procedure for the Insertion of the ALZET™ Osmotic Pump 
The pump was inserted subcutaneously between the scapula of the animal. The animal was 
anaesthetized using a combination of ketamine (80 mg/kg) and xylazine (10 mg/kg) with or 
without inhalant gaseous anaesthesia of 0.5-2% halothane to maintain anaesthesia. The 
animal was then placed on a heating pad to maintain body temperature and the surgery was 
performed on the heating pad. The animal was shaven (mid scapular region) and the area was 
cleaned with a standard solution of 5% hepataine (5ml standard solution of chlorohexadine in 
95ml water). The area was dried with sterile gauze, and betadine (a commercially available 
antiseptic spray) was applied to the area. Contact time of a few minutes was permitted before 
the area was cleaned with sterile swabs. The animal was surgically draped and prepared for 
surgery. A mid-scapular incision of ~1cm was then made with a #10 scalpel blade. Blunt 
dissection was performed with a small forceps and a haemostat to separate skin from fascia in 
order to make a pocket for the pump. When a large enough pocket was made, the filled pump 
was then inserted into this pocket. The incision was closed with nylon sutures (size 2-0 or 3-
0). The surgical area was swabbed and sterilised with betadine. The operated animal was left 
to recover with regular observation for 24 hours. The wound/incision was monitored and 
disinfected twice daily with betadine to prevent infection until the wound/incision had healed 
completely and during this period the animals health status was checked for any adverse 









3.1.3.3. Infusion Dosage 
Angiotensin II, was obtained as a lysate from Sigma (Catalogue No. : A9525) and dissolved 
in Saline (0.9% NaCl) and delivered using the 2004 model ALZET™ mini osmotic pump, at 
a dosage equivalent to 10ng/kg/min-1. This dosage was adopted from previous studies, where 























3.1.4. BLOOD PRESSURE 
Blood pressure was monitored using the non-invasive tail-cuff method. Blood pressure was 
monitored weekly for the duration of the study on all groups. Blood pressure was recorded 
using the II TC Model 31 NIBP blood pressure recording equipment in the Biomedical 
Resource Unit (UKZN-Westville Campus). 
3.1.4.1. Blood Pressure Training Protocol 
All animals were trained during the acclimatisation week. Animals were first exposed to the 
restrainers as a group, by allowing them to explore the restrainers in a communal cage. When 
they gained confidence in moving in and out of the restrainers, they were individually held 
and allowed to walk into the restrainers. This was done over ~2 days. 
The animals were then exposed to the warming chamber and all animals were placed a 
minimum of 3 times in restrainers and placed into the warming chamber for periods not 
exceeding 10 minutes. The animals were then exposed to the tail-cuff, with repetitive 
inflation and deflation cycles. 
3.1.4.2. Blood Pressure Recording Protocol 
Systolic blood pressure, diastolic blood pressure and heart rate measurements were obtained 
by the use of a non-invasive computerized tail-cuff system. The system is comprised of an 
automatic scanner and pump, a tail cuff with a photoelectric sensor and amplifier to measure 
and count the pulse rate in the animals tail (II TC Model 31 NIBP). The principle of operation 
is related to the Riva-Rocca method used in humans. 
Small, medium and large sizes of restraining devices were used. This was to compensate for 
the increase in mass, size and diameter of the tail, of the animals during the 28 day duration 
of the study. The restrainers used were hollow Perspex cylinders, which fitted the rats snugly 
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so as to minimize voluntary movement of the experimental animal, which could have an 
effect on the blood pressure readings. The restrainers allowed for the protrusion of the tail 
through the tail cuff at one end and ventilation of the head at the other end. The tail cuff was 
attached to the restrainer by a studded end plate. 
Animals were allowed to pre-heat in the restrainer for ~20minutes in a warming chamber 
maintained at ~31oC. This was found to be the optimum temperature at which consistent 
pulses could be detected. The warming chamber consisted of a circulating heated fan 
surrounded by ventilated Perspex walls and cover. The warming chamber allowed for 3 
animals to be pre-heated and monitored simultaneously. The optimum temperature in the 
warming chamber was maintained by the heated circulating fan which had a temperature 
control.  
After preheating the animals, the tail cuff was automatically inflated by the pump, which 
resulted in the arterial blood supply to the tail being occluded. The tail cuff was then slowly 
deflated. The reappearance of a pulsation, which was detected by the photoelectric sensor, 
was taken as the systolic blood pressure. As the pressure continued to drop, the computer 
automatically stored the detected high pulse point, which was accepted as the mean pressure 
if there was no subsequent higher pulse pressure within the next two seconds. The diastolic 
pressure for recording was computed using the equation; Diastolic = (3mean – Systolic) / 2, 
this feature was part of the software used (BPMON Version 2.1.). 
The results were displayed as data plots and summary data of systolic, diastolic, mean blood 
pressure and heart rate on the computer screen, this information being available in printable 
form. The blood pressure measurement information was displayed in 2 forms viz. plots of 
analogue waveforms and digital values. The same occluding tail cuff was used for all 
animals, to minimise any variables in blood pressure monitoring. All results were done with 
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the artefact filter switched on. The validation of the method and equipment was previously 





















Animals were sacrificed by exsanguination, at the end of the specified duration, viz. 28 days 
after weanling for both the infused and non-infused groups and at 21 days old for the 
weanling groups. The sacrifice was carried out in the Animal Operating Theatre in the 
Biomedical Resource Unit (UKZN - Westville Campus). Animals were fasted overnight and 
were sacrificed the next morning. Animals were sedated with halothane (5mg/kg) with the 
use of a gas chamber. 
Once fully sedated, blood was collected using a 16 gauge sterilised needle and syringe, via 
cardiac puncture. This blood was aliquoted for the different assays in pre-cooled collection 
tubes as follows: 
1. Superoxide Dismutase  (Whole Blood) 
2. Glutathione Peroxidase  (Whole Blood) 
3. Catalase   (Serum) 
4. Hydrogen peroxide   (Plasma) 
5. Angiotensin II   (Plasma) 
6. Nitric Oxide   (Plasma) 
After the blood collection, the animals abdominal and thoracic cavity was surgically exposed 
and the required tissue viz. arch of aorta, kidney and the required vasculature was dissected 
out. The kidney and aorta were placed in mircocentrifuge tubes and were snap frozen in 
liquid nitrogen and stored in a biofreezer (-700C) for later analysis. The harvested vasculature 
was stored in 10% buffered neutral formalin (BNF) for histological analysis. It should be 
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noted that all harvesting was done immediately, with the time delay kept to a minimum, to 






















3.2.   SAMPLE ANALYSIS 
3.2.1. GLUTATHIONE PEROXIDASE 
Glutathione Peroxidase (GPx) was quantified using a commercially available kit from 
Randox Chemicals (RANSEL - Cat No: RS 504). The method is based on that of Paglia and 
Valentine, (1967). GPx catalyses the oxidation of glutathione (GSH) by cumene 
hydroperoxide. In the presence of glutathione reductase (GR) and NADPH the oxidised 
glutathione (GSSG) is immediately converted to the reduced form with a concomitant 
oxidation of NADPH to NADP+. The decrease in absorbance at 340 nm was measured. 
Reaction series: 
2GSH + ROOH   →  ROH + GSSG + H2O 
GSSG + NADPH + H+ →  NADP+ + 2GSH 
The method allowed for GPx to be quantified in whole blood. The sample, had to be diluted 
using the diluting agent supplied, until the absorbance change per minute was below the 
threshold of 0.1000, set by the supplier. This is done to ensure that there was linearity in the 
equation supplied. GPx was quantified using the following equation that was supplied by the 
agent: Units of GPx / Litre of Haemolysate = 8412  x  ΔAbsorbance (340nm) / Minute 
The reaction was carried out in matched glass cuvettes and readings were obtained from a 






3.2.2. SUPEROXIDE DISMUTASE (SOD) 
Superoxide Dismutase (SOD) was quantified using a commercially available kit from 
Randox Chemicals (RANSOD – Cat No: SD125). The assay principle is based on the role of 
SOD which is to accelerate the dismutation of the toxic superoxide radical (O2-), which is 
produced during oxidative energy processes, to hydrogen peroxide (H2O2) and molecular 
oxygen (O2). The method employs xanthine and xanthine oxidase (XOD) to generate 
superoxide radicals, which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride (I.N.T.) to form a red formazan dye. The SOD activity is then 
measured by the degree of inhibition of this reaction. A standard curve was plotted using the 
standards provided by the kit. During successive assays, a standard was also assayed, to 
ensure that the standard fell into the same range on the standard curve. 
The assay was carried out on an erythrocyte lysate. The lysate was prepared by centrifuging 
0.5ml the aliquoted whole blood for 10 minutes at 3000 rpm at 40C. The buffy coat and 
plasma was aspirated off. The remaining erythrocytes were thoroughly washed with cold 
saline solution (0.9% NaCl). The suspension was then centrifuged for 10 minutes at 3000 rpm 
at 4oC. This washing process was repeated four times to ensure thorough washing of cells.  
The washed and centrifuged erythrocytes were then made up to 2 ml with cold redistilled 
water (Millipore), they were then mixed and left to stand on ice (4oC) for 15 minutes. The 
resulting lysate was then diluted with a 0.01 mmol/l phosphate buffer (pH 7), the dilution was 
done to ensure that the percentage inhibition fell between 30 – 60%, as required by the 
supplier. The reaction was carried out in matched glass cuvettes and readings were obtained 




The percentage inhibition was calculated from the equation supplied by the manufacturer and 
the concentration of SOD was then extrapolated from the percentage inhibition on the 
standard curve. 


















3.2.3. ANGIOTENSIN II 
Ang II was quantified using a commercially available kit from BACHEM (Kit No: S1133). 
The kit was a competitive peptide enzyme immunoassay. The working principle as explained 
in the kit insert is as follows: 
 
Figure 3: Reaction Series for Ang II EIA. 
The antiserum is immobilized on a 96-well plate. A constant concentration of Bt-tracer 
(biotinylated tracer) and varying concentrations of standard/sample compete for binding 
specifically to the anti-serum. Captured Bt-tracer is subsequently bound to SA-HRP 
(streptavidin-conjugated horseradish peroxidase), which produces a soluble coloured product 
after TMB (3,3`,5,5`-tetramethyl benzidine dihydrochloride) is added. This reaction is then 
stopped with 2N hydrochloric acid, and the yellow end point colour (optical density) is read 
on a plate reader at a wavelength of 450 nm. 
The plasma samples had to be first prepared/purified by sample extraction. The following 





Buffer A – 1% triflouroacetic acid (TFA)   
Buffer B – 60% acetonitrile, 1% TFA and 39% distilled water 
3.2.3.2. Procedure 
1. 200 ul of Buffer A was added to an equal volume of sample (plasma) 
2. This was centrifuged at 5000 rpm for 20 minutes at 40C 
3. The supernatant was transferred to a new tubes discarding any pellet that was present 
4. A SEP-COLUMN (containing 200 mg of C18 – Cat No: Y-1000 – BACHEM) was 
equilibrated by washing with 1 ml Buffer B, followed by 3 washes of 3 ml Buffer A 
5. The plasma sample was loaded into the column 
6. The column was slowly washed with Buffer A (3 ml, twice) 
7. The peptide was eluted slowly with Buffer B into a microcentrifuge tube 
8. The eluant was freeze-dried by immersing the tube into liquid nitrogen  
9. The freeze-dried sample was evaporated in a centrifugal evaporator. 
10. The residue was dissolved in a suitable volume of EIA buffer such that the 
concentration of the peptide fell close to the IC50. This dissolved peptide was now 





3.2.4. NITRIC OXIDE 
Nitric oxide was quantified in plasma with the aid of a commercially available kit from 
BioAssay Systems (QuantichromTM Nitric  oxide assay kit – Cat No: DINO 250).  
The final products of NO in vivo are nitrite and nitrate. The relative proportion of nitrite and 
nitrate is variable and cannot be predicted with certainty. Thus the method uses the sum of 
both these species as total NO production. The principle is based on the improved Griess 
method, in two steps, where the first step involves the conversion of nitrate to nitrite utilizing 
a nitrate reductase. The second step involves adding the Griess reagents (i.e. Sulphanilamide 
and Ethylenediamine) which convert nitrite into a deep purple azo compound that can be read 
using a spectrophotometer at 540nm.  














Kidney F2-isoprostanes were evaluated using a commercially available kit from Northwest 
Life Science Specialties (Product Number: NWK-IS001)  
Isoprostanes are prostaglandin-like compounds that are produced by free radical mediated 
peroxidation of lipoproteins. Levels of 15-isoprostane F2t a representative isoprostane in 
biological fluids, has been shown to be useful for assessment of oxidant stress in vivo.  
This assay according to the supplier utilizes a competitive enzyme-linked immunoassay 
format. Briefly, 15-isoprostane F2t in the samples or standards is allowed to compete with 15-
isoprostane F2t conjugated to horseradish peroxidise (HRP) for binding to a polyclonal 
antibody specific for 15-isoprostane F2t coated on the microplate. Subsequent TMB 
(3,3`,5,5`-tetramethyl benzidine dihydrochloride) substrate addition results in a blue colour 
development that is inversely proportional to the quantity of 15-isoprostane F2t in the original 
samples or standards. Addition of an acid stop solution causes a colour change to yellow 
where absorbance is read at 450nm on a microplate reader. 
The following solid phase extraction (SPE) protocol was used to extract the 15-isoprostane 
F2t fraction from the kidney. 
3.6.1. Reagents 
1. Folch Solution: 
2:1 Chloroform:Methanol + 5 mg Butalyated Hydroxytoulene (BHT)/100 ml solution 
2. Methanol Solution: 
Methanol (MeOH) + 5 mg BHT/100 ml MeOH 
3. 15% Potassium Hydroxide (KOH) 
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4. pH 3.0 water 
5. Ethyl acetate Heptane solution: 
Ethyl acetate : Heptane (1:1) 
6. Ethyl acetate Methanol solution 
Ethyl acetate : Methanol (1:1) 
3.6.2. Procedure 
1. 20 ml of Folch solution was added to a 40 ml flat bottom centrifuge tube, and placed 
on ice. 
2. The kidney was weighed and between 0.5 - 1 g of tissue was added to the Folch 
Solution on ice. 
3. The tube was vortexed vigorously for 1 min. 
4. The solution was homogenised with a blade homogeniser for 30 seconds. 
5. The homogenate solution was placed under nitrogen (N2) for 1 hour at room 
temperature, and was vortexed occasionally. 
6. 4 ml of saline (0.9% NaCl) was added to the homogenate solution and vortexed 
vigorously. 
7. The homogenate solution was centrifuged at 5000 rpm for 3 minutes. 
8. The upper aqueous layer (MeOH/saline) was discarded. 
9. The lower phase was transferred to a glass 50 ml conical test tube (much care was 
taken to avoid the middle protein layer). 
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10. This solution was evaporated under N2. 
11. When the solution had fully evaporated, 2 ml of MeOH+BHT, as well as an equal 
volume of 15% KOH were added to the test tube. 
12. The solution was incubated in a water-bath maintained at 37OC for 30 minutes. 
13. The solution was diluted with 40 ml of pH 3.0 water so that the MeOH was less than 
5% of the total volume. This sample was then ready for the solid phase extraction. 
14. 3 ml of pH 3.0 water was added to 10 ml of the diluted sample. 
15. The pH of this solution was adjusted to 3. 
16. C-18 Sep Pak: 
i. The column was washed with 5 ml ethanol 
ii. This was followed with 5 ml pH 3.0 water 
iii. The sample was loaded 
iv. The column was washed with 10 ml pH 3.0 water 
v. The column was washed with 10 ml Heptane 
vi. The peptide was eluted with 10 ml Ethyl acetate: Heptane (1:1) solution into a 
plastic tube. 
vii. 1 pea-sized scoop of sodium sulphate was added to the eluant. 
viii. The eluant was aspirated into a new test tube with a disposable pipette.  
ix. The sample was ready for the next column. 
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17. Silica Sep-Pak 
i. The column was washed with 5 ml MeOH 
ii. This was followed with 5 ml ethyl acetate 
iii. The sample was loaded (i.e. the Ethyl acetate:Heptane eluant) 
iv. The column was washed with 5 ml ethyl acetate 
v. The peptide was eluted with 5 ml of an Ethyl acetate:Methanol (1:1) solution 
into a plastic tube. 
vi. This solution was evaporated under N2 













3.2.6. HYDROGEN PEROXIDE 
Hydrogen Peroxide (H2O2) was quantified in plasma using a commercially available kit from 
Assay Designs – Stressgen (Catalogue Number: 907-015). The kit was a simple colorimetric 
assay based on the following working principle as explained in the kit insert.  
The kit is designed to measure low concentrations of H2O2 in biological matrices. The 
principal is based on a colour reagent that contains a dye, called xylenlol orange, in an acidic 
solution with sorbitol and ammonium iron sulphate that reacts to produce a purple colour that 
is proportional to the concentration of H2O2, in a sample. This colour change was then read at 















Catalase levels were quantified in serum using a biochemical assay, based on a modified 
method adapted from Goth., (1991). The serum was obtained by allowing blood to stand at 
room temperature for 30 minutes in a glass serum tube upon collection, the clot was then 
removed via centrifugation at 3000 rpm for 10 minutes and the serum was aspirated and 
stored at -70oC.    
3.2.7.1. Reagents  
1. Substrate – 65 umol/ml H2O2 in 60 mmol/l Na-K phosphate buffer (pH 7.4) 
                       30% H2O2 (0.05525 g/25 ml) 
2. 32.4mmol/l Ammonium molybdate – Na2HPO4.2H2O (40.05 g/l) 
3. Buffer (phosphate) for dilution of sample (If > 100 kU/l) – 2-10 fold 
4. Na-K buffer – 60 mmol/l (pH 7.4) 
 a) KH2PO4   - 8.165 g/l 
 b) Na2HPO4.2H2O - 10.679 g/l 
 For 100ml buffer a (19.7 ml) + b (80.3 ml) – Mix, adjust pH to 7.4 
3.2.7.2. Procedure 
Sample :   
i) 0.2 ml serum was added to 1 ml of substrate  
ii) This was incubated at 370C for 1 minute 
iii) The reaction was stopped with 1 ml (NH4)6Mo7O24) 
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iv) The optical density was read at 405 nm against Blank 3 
The reaction series was prepared as follows: 
Blank 1: 0.2 ml serum + 1 ml substrate + 1 ml (NH4)6Mo7O24 
Blank 2: 0.2 ml buffer + 1 ml substrate + 1 ml (NH4)6Mo7O24 
Blank 3: 0.2 ml buffer + 1 ml buffer      + 1 ml (NH4)6Mo7O24  
The reactions were carried out in matched glass cuvettes and readings were obtained from a 
dual beam spectrophotometer (Varian, Cary IE).  
Serum catalase activity was calculated using the following formula: 














3.2.8.1. TISSUE PROCESSING 
The vasculature was removed from the fixative i.e. 10% BNF. The need for fixation was to 
ensure that the integrity of the cellular components of the tissue was maintained, as is 
standard procedure for histological study. 
Histoprocessing was conducted with the use of the H2500 microwave processor. The tissue 
was placed in appropriately labelled cassettes that were immersed in a plastic beaker 
containing ethyl alcohol (100%). The beaker was thereafter placed in the microwave 
processor, with the temperature probe manoeuvred centrally into the bath. The microwave 
processor power level was turned to 450W (80%) and the temperature set at 670C for 15 
minutes. 
After the set time had elapsed, the cassettes were removed and placed in a bath containing 
isopropanol. This bath was placed in the microwave processor with the temperature probe 
being centered again. The microwave processor was then set at 450 W (80%) and 750C for 15 
minutes. The cassettes were then placed into a paraffin rack, and immersed into a plastic 
beaker containing melted paraffin, the paraffin’s melted state being maintained on a stove at 
670C. 
The plastic beaker containing the paraffin and cassettes was then placed into the microwave 
processor. Microwave processing in paraffin was carried out in two steps at different 
temperature settings viz. 700C for 10 minutes and 820C for 10 minutes. 




3.2.8.2.    EMBEDDING 
3.2.8.2.1. Embedding Equipment 
The embedding procedure was carried out with the use of the Shandon Histocentre 2. The 
equipment essentially consists of a paraffin tank, cold plate, hot plate, base moulds, a pair of 
warmed forceps and a warming tank. 
3.2.8.2.2. Embedding Procedure 
The processed vasculature was placed in a stainless steel holding tank containing molten 
paraffin. These cassettes were then removed and placed in the warming tank. 
An appropriate base mould was then selected from the prewarmer which housed various base 
moulds of differing sizes. The mould was placed on the hot plate and paraffin wax was 
dispensed from the paraffin tank into the mould, filling it to about quarter of the level of the 
base mould.  
The tissue from the warming tank was orientated in the base mould so as to have the exposed 
portions of the vessel facing down. The tissue was then held in position with a pair of heated 
forceps and placed on the cold plate. The molten paraffin then changed from translucent to 
opaque and it hardened. Thereafter an appropriately labelled cassette was placed on top of the 
base mould and filled with the molten wax. The base mould was then placed back on the cold 
plate for rapid cooling and hardening of the molten wax. After the right amount of cooling 
was achieved, the specimen attached to the cassette was carefully removed from the base 





3.2.8.3.    SECTIONING 
3.2.8.3.1. Trimming the wax block 
A rotary microtome was used for the cutting of paraffin embedded serial sections. The coarse 
feed mechanism of the microtome was advanced by hand before commencement of each 
stroke. This was done in order to trim away the surplus wax and to expose an appropriate area 
of tissue for sectioning. On exposing a suitable area a thickness of 2μm was chosen for 
sectioning. 
3.2.8.3.2. Cutting Sections 
The paraffin blocks were placed on ice before cutting. This is done because the integrity of 
the paraffin block is dependent on atmospheric temperature, melting point of wax and 
humidity. However, if contact is limited on the block face this is not detrimental and this 
cooling effect on the block face by the ice promotes ease in production of flat sections. 
It was found that blowing lightly on the section the moment the section commenced up the 
cutting edge of the knife was beneficial in obtaining a consistent ribbon of wax. Warm breath 
had an expansion effect on the wax, thereby flattening the cut sections. The selected sections 
were then immediately floated out on a constant temperature water bath (60oC). 
3.2.8.3.3. Floating out of Sections 
The floating out actions had to be smooth, with the trailing end of the ribbon making contact 
with the hot water bath first. The slight drag produced when the ribbon touches the water 
surface is sufficient to produce tension in the ribbon and to thereby remove most of the folds 
from these sections. 
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The remaining wrinkles and folds were removed by carefully teasing them apart with a pair 
of forceps, as the ribbon came to rest on the water surface. After several minutes on the water 
surface, complete flattening and expansion of sections were achieved. Prolonged floating was 
avoided since this may cause the tissue to expand beyond their normal size and become 
distorted or irregular. 
The hot water bath was maintained at a temperature of ~60oC. A higher temperature would 
cause the paraffin to melt and dissolve sections, and a lower temperature would not have the 
desired effect of flattening out the sections. 
3.2.8.3.4. Temporary Mounting 
Once the sections were evenly flattened on the water bath, they were separated into 
individual sections or groups of sections. The desired sections were picked up on a clean, 
appropriately labelled slide, which was previously coated with egg albumen. The slide was 
placed approximately three quarters into the water bath and was manoeuvred so as to position 
the tissue in a desired position on the coated side. The slide was then slowly picked up with 
the section safely flattened onto the slide. The egg albumen used is a general purpose section-
adhesive. It is an adhesive which results in a minimal production of background staining. 
The slides were then tapped vertically on a paper towel to remove excess water and placed on 
a warming plate. The warming plate was maintained at a temperature of ~400C, and the slides 
were placed on it for ~8 minutes to provide maximal adhesion of the tissue section to the 






3.2.8.4. SLIDE SELECTION 
Twelve slides for each animal, in each group were chosen for staining. These slides were 
chosen on the context of well sectioned slides.  
3.2.8.5. STAINING 
3.2.8.5.1. Principle 
Staining was done using a basic Haematoxylin-Eosin stain. Haematoxylin stains the nuclear 
component and eosin is responsible for cytoplasmic staining. In the first step, the nuclei are 
stained with a haematoxylin solution. The nuclei stain blue, dark violet to black. The second 
step is counterstaining with eosin, where the cytoplasmic portions stain pink. This stain 
therefore allows for the identification of individual cells, as well as components. 
3.2.8.5.2. Reagents 
The following reagents were made up in the Physiological Chemistry Laboratory in the 
Department of Human Physiology: 
1. Harris Haematoxylin 
Haematoxylin  : 10 g 
Absolute Alcohol  : 100 ml 
Potassium Alum  : 200 g 
Distilled Water  : 2000 ml 
Mercuric Oxide  :5g 
The haematoxylin was dissolved in the absolute alcohol in a small beaker. The potassium 
alum was then dissolved in warm distilled water in 5 litre flask and brought up to boiling 
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point. The mixture was then removed from the heat and the mercuric oxide was added and 
then cooled rapidly in a sink of iced water. The reagent was now ready for use and stored in a 
light safe holding vessel. 
2.   Eosin 
Eosin Y    : 1 g 
Distilled Water   : 20 ml 
Ethanol (100%)   : 80 ml 
The Eosin Y was dissolved in distilled water and then added to the ethanol. A working 
solution was then made up in a 1:2 ratio with 70% ethanol. 0.5 ml of glacial acetic acid was 
added to each 100 ml of stain just before use. 
3. Acid Alcohol 
70% Alcohol   : 70 ml 
Concentrated Hydrochloric Acid : 2 ml 
Distilled Water   : 28 ml 
The hydrochloric acid was added to the alcohol in a fume cupboard, and the distilled water 
was added to this mixture to bring the solution up to a 100 ml.  
3.2.8.5.3. Procedure 
Eight slides were stained on each staining run, in appropriate staining glassware. The time for 
each step was monitored using a stop watch. 
1. The slides were first de-paraffinised by immersing them into a solution of xylene for 2 
minutes. This step was repeated 3 times.  
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2. The tissue was hydrated to water. This was achieved by using decreasing 
concentrations of alcohol. The tissue was first placed into a 100% solution of alcohol 
for 1 minute. This step was repeated two more times. The tissue was then placed into 
a 95% solution of alcohol for 1 minute and this was also repeated two more times. 
The tissue was thereafter placed into 90%, 80% and 70% alcohol solutions 
respectively for a period of 1 minute each. Finally the tissue was washed twice in 
distilled water, with each slide set being dipped 10 times. This step completed the 
hydration of the tissue.  
3. The hydrated tissue was immersed into the Haematoxylin solution for 1 minute. 
4. The slides were dipped into distilled water to remove the excess stain. 
5. The slides were washed under running tap water for 10 minutes. This was done to 
remove the excess Haematoxylin and to prevent over-staining. 
6. The slides were immersed in the Acid Alcohol solution for 1 minute. 
7. The slides were washed twice in distilled water, for 2 minutes for each wash. 
8. The slides were immersed in the eosin solution for 1 minute. 
9. The tissue was dehydrated. This was achieved by placing the tissue in increasing 
concentrations of alcohol. The tissue was first placed in a 70% solution of alcohol for 
1 minute. The tissue was thereafter immersed into 80%, 90% and 95% alcohol 
solutions for 1 minute each. The tissue was then placed into absolute alcohol (100%) 
for 1 minute. This step was repeated 3 times.  
10. The slides were cleared by placing them in Xylene, for a period of 2 minutes. This 
was repeated 3 times. 
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The slides were then ready to be permanently mounted. 
3.2.8.5.4. Permanent Mounting 
The stained sections were immediately mounted by placing the slide on a coverslip, which 
had a drop of DPX™ mountant on them. Pressure was applied to the slide so as to spread the 
DPX™ evenly and prevent the formation of air bubbles. The mounted sections were allowed 
to dry for 24 hours.  
The slides were then ready for histological analysis. 
3.2.8.6. MORPHOMETRIC ANALYSIS 
Slides were analysed in the Electron Microscope Unit (EMU) at the University of Kwa-Zulu 
Natal - Westville Campus. 
Slides were viewed under a Nikon Compound Microscope, at 10x magnification. Images 
were captured using a Nikon DS U2/L2 camera, with the aid of NIS Elements D 3.0 histology 
software. Morphometric measurements on captured images were then made, with the use of 
the iTEM software. Each image was first calibrated at a 10x magnification scale, and then 
measurements were made. The software allowed for measurement of area and perimeter in 








3.2.9. GENE EXPRESSION AND ANALYSIS 
3.2.9.1. Trizol purification of RNA 
(Perou et al. 1999) 
1. The frozen tissue specimen was removed from the bio-freezer and using a scalpel, the 
tissue was cut into small pieces. 1 ml Trizol was added per 50-100 mg tissue processed. This 
tissue was then homogenized in the Trizol until it could easily pass through a 21 gauge 
needle. 
2. The sample was incubated at room temperature for 5 to 10 minutes after homogenization. 
3. The sample was centrifuged at 12000 rpm for 20 minutes at 40C. 
4.  The upper fat layer was removed using a Pasteur pipette (Upper fat layer, if present has a 
yellowish appearance while the Trizol homogenate, remains red.) 
5. 200 ul chloroform per 1 ml Trizol reagent used in step 2 was added to the sample. The 
solution was shaken vigorously for 15-30 seconds and incubated at room temperature for 20 
minutes. 
6. The sample was centrifuged at 12000 rpm for 20 minutes at 40C.  
7. The upper aqueous phase which contains the total RNA was carefully removed, and placed 
into a new micro-centrifuge tube.  
8. The RNA was precipitated by adding 500 ul isopropanol and 1 ul glycogen per 1 ml Trizol. 
This was thereafter incubated at room temperature for 20 minutes. 
9. The solution was centrifuged at 12000 rpm for 20 minutes at 40C. 
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10. The supernatant was carefully discarded and the remaining pellet was washed once with 
1ml 75% ethanol per 1 ml Trizol.  
11. This solution was centrifuged at 12000 rpm for 10 minutes at 40C. 
12. The resulting supernatant was discarded and the sample was centrifuged for 1 minute to 
remove residual ethanol. 
13. The resulting pellet was immediately redissolved in 35 ul of RnaSecure. 
14. The solution was placed in an oven at 60oC for 10 minutes. 
15. The sample was stored in a biofreezer at -70oC. 
16. The samples thereafter underwent a DNAse treatment to remove residual genomic DNA 
from the extracted sample. 
17. This sample thereafter underwent cDNA synthesis using a commercially available kit by 
BioRad (iScript cDNA synthesis kit) 










3.2.9.2. Realtime PCR quantification 
3.2.9.2.1. p22phox 
p22phox gene expression was examined by using SYBR Green 1 (Roche Diagnostics) 
chemistry with primers obtained from Inqaba Biotech to uniquely amplify the p22phox 
sequence. The primers for p22phox were 5’-GCTCATCTGTCTGCTGGAGTA-3’ (forward) 
and 5’-ACGACCTCATCTGTCACTGGA-3’ (reverse). The housekeeping gene used was 
GAPDH. The primers for GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) were 5’-
TCCATGACAACTTTGGCATC-3’ (forward) and 5’-CATGTCAGATCCACCACGGA-3’ 
(reverse), (Moritz et al., 2003).  Each real-time PCR reaction was performed in a total 
volume of 10 ul that was made up of 5.05 ul water, 1.2 ul MgCl2 (3 mmol/ul), 0.5 ul reverse 
primer, 0.25 ul of forward primer, 1 ul Fast Start SYBR Green I and 2 ul sample cDNA. All 
reactions were run in a Roche Lightcycler Ver. 1.5 with 1 cycle of 95oC (10 minutes), 
followed by 45 cycles of 95oC (6 seconds), 58oC (10 seconds) and 72oC (6 seconds). Each 
sample was run in duplicate. Relative mRNA copy numbers were calculated by generating 
standard curves using serial dilutions of a known concentration of cDNA. p22phox and 
GAPDH mRNA levels were calculated as number of molecules per ug of cDNA. Results that 









gp91phox gene expression was examined by using SYBR Green 1 (Roche Diagnostics) 
chemistry with primers obtained from Inqaba Biotech to uniquely amplify the gp91phox 
sequence. The primers for gp91phox were 5’-CCAGTCTGAGACTCAAAAAGATCTACT 
TC-3’ (forward) and 5’-GTCTGCGAACCACTCAAAAGC-3’ (reverse). The housekeeping 
gene used was GAPDH. The primers for GAPDH were 5’-TCCATGACAACTTTGGCATC-
3’ (forward) and 5’-CATGTCAGATCCACCACGGA-3’ (reverse), (Moritz et al., 2003).  
Each real-time PCR reaction was performed in a total volume of 10 ul that was made up of 
4.8 ul water, 1.2 ul MgCl2 (3 mmol/ul), 0.5 ul reverse primer, 0.5 ul of forward primer, 1 ul 
Fast Start SYBR Green I and 2ul sample cDNA. All reactions were run in a Roche 
Lightcycler Ver. 1.5 with 1 cycle of 95oC (10 minutes), followed by 42 cycles of 95oC (6 
seconds), 60oC (6 seconds) and 72oC (6 seconds). Each sample was run in duplicate. Relative 
mRNA copy numbers were calculated by generating standard curves using serial dilutions of 
a known concentration of cDNA. gp91phox and GAPDH mRNA levels were calculated as 
number of molecules per ug of cDNA. Results that follow are depicted as a ratio of gp91phox 











Cu/Zn-SOD gene expression was examined by using SYBR Green 1 (Roche Diagnostics) 
chemistry with primers obtained from Inqaba Biotech to uniquely amplify the Cu/Zn-SOD 
sequence. The primers for Cu/Zn-SOD were 5’-CGGATGAAGAGAGGCATGTTG-3’ 
(forward) and 5’-TTGGCCACACCGTCCTTT-3’ (reverse) (van Lindhout et al., 2008). The 
housekeeping gene used was GAPDH. The primers for GAPDH were 5’-
TCCATGACAACTTTGGCATC-3’ (forward) and 5’-CATGTCAGATCCACCACGGA-3’ 
(reverse) (Moritz et al., 2003).  Each real-time PCR reaction was performed in a total volume 
of 10 ul that was made up of 4.8 ul water, 1.2 ul MgCl2 (3 mmol/ul), 0.5 ul reverse primer, 
0.5 ul of forward primer, 1 ul Fast Start SYBR Green I and 2 ul sample cDNA. All reactions 
were run in a Roche Lightcycler Ver. 1.5 with 1 cycle of 95oC (10 minutes), followed by 40 
cycles of 95oC (6 seconds), 58oC (10 seconds) and 72oC (6 seconds). Each sample was run in 
duplicate. Relative mRNA copy numbers were calculated by generating standard curves 
using serial dilutions of a known concentration of cDNA. Cu/Zn-SOD and GAPDH mRNA 
levels were calculated as number of molecules per ug of cDNA. Results that follow are 










AT-1a gene expression was examined by using SYBR Green 1 (Roche Diagnostics) 
chemistry with primers obtained from Inqaba Biotech to uniquely amplify the AT-1a 
sequence. The primers for AT-1a were 5’-CGGATGAAGAGAGGCATGTTG-3’ (forward) 
and 5’-TTGGCCACACCGTCCTTT-3’ (reverse) (Naito et al., 2002). The housekeeping gene 
used was GAPDH. The primers for GAPDH were 5’-TCCATGACAACTTTGGCATC-3’ 
(forward) and 5’-CATGTCAGATCCACCACGGA-3’ (reverse) (Moritz et al., 2003).  Each 
real-time PCR reaction was performed in a total volume of 10 ul that was made up of 4.8 ul 
water, 1.2 ul MgCl2 (3 mmol/ul), 0.5 ul reverse primer, 0.5 ul of forward primer, 1 ul Fast 
Start SYBR Green I and 2 ul sample cDNA. All reactions were run in a Roche Lightcycler 
Ver. 1.5 with 1 cycle of 95oC (10 minutes), followed by 45 cycles of 95oC (6 seconds), 65oC 
(6 seconds) and 72oC (6 seconds). Each sample was run in duplicate. Relative mRNA copy 
numbers were calculated by generating standard curves using serial dilutions of a known 
concentration of cDNA. AT-1a and GAPDH mRNA levels were calculated as number of 
molecules per ug of cDNA. Results that follow are depicted as a ratio of AT-1a to GAPDH 















All data is represented as the Mean ± Standard Error of Mean (SEM). The statistical analysis 
of all the results presented was performed using Graphpad Instat Ver. 5.0. The statistical 
analysis performed was a one-way analysis of variance (ANOVA) and an unpaired t-test.  

















4.1. BLOOD PRESSURE 
The blood pressure was monitored weekly using the non-invasive tail-cuff method. The 
systolic and diastolic blood pressures are shown in Table 6 and are represented in Figure 5 
and Figure 6 respectively. 
4.1.1. Systolic Blood Pressure (SBP) 
The results show that there was a gradual increase in the SBP of the SHR group over the 4 
successive weeks of the study when compared to the normotensive Wistar control, which had 
a steady SBP over the successive weeks (Week 1 – 140 ± 2 mmHg vs 117 ± 1 mmHg; Week 
2 - 149 ± 2 mmHg vs 126 ± 1 mmHg; Week 3 – 173 ± 3 mmHg vs 126 ± 2 mmHg and Week 
4 – 176 ± 1 mmHg vs 124 ± 1 mmHg) 
The Angiotensin II infusion had a significant increase on the SBP of both the SHR and the 
Wistar groups when compared to their respective saline infused controls. The increase in the 
SHR-Ang II infused groups SBP was observed from the first week of infusion until the 
termination of the group in the third week. (Week 1 - 161 ± 3 mmHg vs 143 ± 4 mmHg; 
Week 2 – 179 ± 2 mmHg vs 157 ± 2 mmHg and Week 3 – 207 ± 11 mmHg vs 168 ± 2 
mmHg). The Wistar-Ang II infused group had a significant increase in SBP in the third and 
fourth week of the study when compared to the saline infused control. (Week 1 – 132 ± 3 
mmHg vs 116 ± 2 mmHg; Week 2 - 134 ± 4 mmHg vs 126 ± 1 mmHg; Week 3 – 149 ± 7 









4.1.2. Diastolic Blood Pressure (DBP) 
The results show that there was an increase in the DBP of the SHR group between Week 2 
and Week 3, with the DBP stabilizing from Week 3 till the end of study. This increase in 
DBP was statistically significant when compared to the normotensive Wistar control, which 
showed a stable normotensive DBP, through the entire duration of the study. (Week 1 – 88 ± 
1 mmHg vs 77 ± 1 mmHg; Week 2 - 102 ± 1 mmHg vs 81 ± 1 mmHg; Week 3 – 124 ± 1 
mmHg vs 80 ± 2  mmHg and Week 4  – 123 ± 1 mmHg vs 83 ± 1  mmHg)  
The Ang II infusion showed a significant weekly increase in the DBP of both the SHR and 
Wistar infused groups, when compared to their respective saline-infused control groups. The 
SHR-Ang II infused group had a significant increase in DBP from Week 2 of the infusion till 
the termination of the group at the end of the third week. (Week 1 – 100 ± 3 mmHg vs 94 ± 2  
mmHg; Week 2 - 116 ± 1 mmHg vs 105 ± 2 mmHg; Week 3 – 131 ± 7 mmHg vs 121 ± 2  
mmHg )  
The Wistar-Ang II infused group had a significant increase in DBP from Week 3 till the end 
of study at 4 weeks, this when compared to its respective saline infused control (Week 1 – 89 
± 2 mmHg vs 80 ± 1 mmHg; Week 2 - 89 ± 4 mmHg vs 82 ± 1 mmHg; Week 3 – 100 ± 4 










4.2. HEART RATE 
The heart rate (HR) was monitored weekly, using the non-invasive tail cuff method for 
measuring blood pressure. The heart rates are shown in Table 6 and represented as beats per 
minute (bpm) in Figure 7. 
The results show that the SHR had a steady decrease in HR over the successive weeks (Week 
1 –407 ± 5 bpm; Week 2 - 380 ± 5 bpm; Week 3 – 378 ± 7 bpm; Week 4 - 372 ± 9 bpm). The 
normotensive Wistar control showed a similar trend with a steady weekly decrease in HR 
(Week 1 – 450 ± 10 bpm; Week 2 - 399 ± 8 bpm; Week 3 – 368 ± 9 bpm; Week 4 - 357 ± 18 
bpm). The SHR group had a higher HR than the normotensive Wistar control at the end of 
study (372 ± 9 bpm vs 357 ± 18 bpm), but this higher HR was not statistically significant 
(p>0.05). 
The Ang II infusion caused an increase in the HR of the SHR group at the termination of the 
group at the end of 3 weeks when compared to its saline infused control, at the same time 
(392 ± 5 bpm vs 372 ± 8 bpm), this increase in HR was however not statistically significant 
(p>0.05).  
The Wistar-Ang II infused group, showed a decrease in the HR in the first 2 weeks of 
infusion and then subsequently the HR returned to the saline-infused value at the end of study 
(Week 1 – 398 ± 6 bpm vs 420 ± 8 bpm; Week 2 – 366 ± 7 bpm vs 399 ± 9 bpm; Week 3 – 









Table 6. Systolic Blood Pressure, Diastolic Blood Pressure and Heart Rate  
SYSTOLIC BLOOD PRESSURE (mmHg) 
 Week 1 Week 2 Week 3 Week 4 
SHR 140 ± 2* 149 ± 2* 173 ± 3* 176 ± 1* 
Wistar 117 ± 1 126 ± 1 126 ± 2 124 ± 1   
SHR - Weanling 138 ± 3* - - - 
Wistar - Weanling 120 ± 1 - - - 
Wistar - Saline 116 ± 2 126 ± 1 123 ± 1 121 ± 2 
Wistar - Ang II 132 ± 3* 134 ± 4 149 ± 7* 152 ± 6* 
SHR - Saline 143 ± 4 157 ± 2 168 ± 4 176 ± 3 
SHR - Ang II 161 ± 3* 179 ± 2* 207 ± 11* - 
     
DIASTOLIC BLOOD PRESSURE (mmHg) 
 Week 1 Week 2 Week 3 Week 4 
SHR 88 ± 1* 102 ± 1* 124 ± 1* 123 ± 1* 
Wistar 77 ± 1 81 ± 1 80 ± 2 83 ± 1 
SHR - Weanling 89 ± 1* - - - 
Wistar - Weanling 80 ±1 - - - 
Wistar - Saline 80 ± 1 82 ± 1 83 ± 1 79 ± 1 
Wistar - Ang II 89 ± 2* 89 ± 4 100 ± 4* 99 ± 4* 
SHR - Saline 94 ± 2 105 ± 2 121 ± 2 120 ± 1 
SHR - Ang II 100 ± 3 116 ± 1* 131 ± 7* - 
     
HEART RATE (beats per minute) 
 Week 1 Week 2 Week 3 Week 4 
SHR 407 ± 5* 380 ± 5 378 ± 7 372 ± 9 
Wistar 450 ± 10 399 ± 8 368 ± 9 357 ± 18 
SHR - Weanling 421 ± 6 - - - 
Wistar - Weanling 409 ± 17 - - - 
Wistar - Saline 420 ± 8 399 ± 9 372 ± 11 357 ± 12 
Wistar - Ang II 398 ± 6* 366 ± 7* 374 ± 11 361 ± 8 
SHR - Saline 364 ± 4 353 ± 7 372 ± 8 346 ± 8 
SHR - Ang II 394 ± 10* 374 ± 9 392 ± 5* - 








4.3. PLASMA ANGIOTENSIN II 
Angiotensin II levels were quantified in the plasma of all groups. The levels are shown in 
Table 7 and represented in Figure 8. The results show that the SHR-normal group had a 5.6 
fold higher plasma Ang II concentration than the normotensive Wistar control (8.99 ± 1.22 vs 
1.61 ± 0.43 pg/ml), and this higher concentration was statistically significant (p<0.0001). 
The SHR-weanling group showed no significant difference in plasma Ang II levels when 
compared to the Wistar-weanling (5.33 ± 1.42 vs 4.72 ± 0.59 pg/ml). The SHR-adult group 
showed a 1.7 fold increase in Ang II levels when compared to the SHR-weanling group (8.99 
± 1.22 vs 5.33 ± 1.42 pg/ml), and this difference in Ang II levels was statistically significant. 
(p>0.05). This trend was the opposite when the Wistar-adult group was compared to the 
Wistar-weanling group, with the Wistar-adult group having a 2.9 fold lower plasma Ang II 
level than the Wistar-weanling group (1.61 ± 0.43 vs 4.72 ± 0.59 pg/ml), and this difference 
was statistically significant (p<0.001). 
The SHR-Ang II infused group showed a 3.4 fold decrease in plasma Ang II levels when 
compared to the SHR-saline infused control group (2.79 ± 0.81 vs 9.54 ± 1.30 pg/ml), and 
this decrease was statistically significant (p<0.001). 
The Wistar-Ang II infused group did not demonstrate the same trend and showed no 
significant change in plasma Ang II levels when compared to its saline infused control (1.21 
± 0.25 vs 1.13 ± 0.28 pg/ml). 
The degree of change due to the infusion of Ang II with regards to the plasma Ang II levels 
in the SHR and Wistar was compared and these results show that the sub-pressor dose of Ang 
II decreased plasma Ang II levels in the SHR by 71%, and did not change the plasma Ang II 






4.4. PLASMA NITRIC OXIDE 
Nitric oxide (NO) levels were quantified in the plasma. The levels are shown in Table 7 and 
represented in Figure 9. The results show that the SHR had a 1.4 fold lower plasma NO level 
when compared to its normotensive Wistar control (38.4 ± 1.5 vs 53.7 ± 2.9 ug/ml). This 
difference in plasma NO levels was statistically significant (p<0.05). 
The SHR-weanling showed no difference in the plasma NO level when compared to the 
Wistar-weanling control (62.6 ± 6.0 vs 64.1 ± 5.1 ug/ml). When the SHR-adult group was 
compared to SHR-weanling group, the SHR-adult group showed a 1.6 fold decrease in the 
plasma NO level (38.4 ± 1.5 vs 62.6 ± 6.0 ug/ml), and this difference was statistically 
significant (p<0.05). The Wistar-adult showed a similar trend with a 1.2 fold decrease when 
compared to the Wistar-weanling (53.7 ± 2.9 vs 64.1 ± 5.1 ug/ml), however this decrease was 
not statistically significant (p>0.05). 
The SHR-Ang II infused group had a 1.6 fold lower plasma NO level than the saline infused 
control (24.2 ± 2.9 vs 38.0 ± 1.5 ug/ml), and this decrease was statistically significant 
(p<0.05).  
The Wistar-Ang II infused group showed a similar trend with a 1.1 fold decrease in plasma 
NO levels (47.9 ± 1.0 vs 54.2 ± 6.2 ug/ml), this decrease was however not statistically 
significant (p>0.05). 
The degree to which the infusion of the sub-pressor dose of Ang II decreased the plasma NO 
levels in the SHR and Wistar was compared, and the results show that in the Wistar infused 
with Ang II, the NO levels were decreased by 13%, but the SHR infused with Ang II showed 




















  :Statistically significant difference when compared to the Wistar group 
* Wistar     :Statistically significant difference when compared to the Wistar-Weanling group  
*SHR-Weanling  :Statistically significant difference when compared to the SHR group 
* Wistar-Weanling :Statistically significant difference when compared to the SHR-Weanling  group 
*Wistar-Ang II :Statistically significant difference when compared to the Wistar-Saline infused group 
*SHR-Ang II  :Statistically significant difference when compared to the SHR-Saline infused group 
N.B. Red % – below the Wistar and SHR Ang II group values, means % increase ()/decrease() compared to the respective Saline infused control 





















































38.4 ± 1.5* 53.7 ± 2.9 62.6 ± 6.0* 64.1 ± 5.1 54.2 ± 6.2 47.9 ± 1.0 (12%) 38.0 ± 1.5 
































































4.5. SUPEROXIDE DISMUTASE  
SOD was quantified in the vascular compartment (red blood cell). The results are shown in 
Table 8 and represented in Figure 10. 
The SHR group had a 1.1 fold higher SOD level than the normotensive Wistar control (69.3 ± 
1.1 vs 61.5 ± 1.5 SOD units/ml), and this increase was statistically significant (p>0.05). The 
SHR-weanling group showed no difference in SOD levels when compared to the Wistar-
weanling (49.6 ± 3.9 vs 51.0 ± 1.8 SOD units/ml), however when the SHR-adult was 
compared to the SHR-weanling, there was a statistically significant (p<0.05) 1.4 fold increase 
in SOD levels (69.3 ± 1.1 vs 49.6 ± 3.9 SOD units/ml) in the SHR adult group. This trend 
was the same when the Wistar-adult group was compared to the Wistar-weanling group, with 
the Wistar-adult group having a 1.2 fold increase in SOD levels (61.5 ± 1.5 vs 51.0 ± 1.8 
SOD units/ml), and this difference was also statistically significant (p<0.001). 
The SHR-Ang II infused group demonstrated a 1.1 fold decrease in SOD concentration when 
compared to the saline infused control group (63.4 ± 4.6 vs 70.2 ± 4.9 SOD units/ml), but this 
difference was not statistically significant (p>0.05). 
The Wistar-Ang II infused group also showed a similar trend with a 1.2 fold decrease in SOD 
levels (54.5 ± 2.6 vs 65.4 ± 4.2 SOD units/ml), and this difference was also not statistically 
significant (p>0.05). 
The degree to which the infusion of the sub-pressor dose of Ang II decreased the SOD levels 
in the SHR and Wistar was compared, and the results show that in the Wistar infused with 
Ang II, the SOD levels were decreased by 17%, and the SHR infused with Ang II, showed a 







4.6. GLUTATHIONE PEROXIDASE 
GPx was quantified in whole blood and the results are shown in Table 8 and represented in 
Figure 11. 
The SHR group showed a 1.8 fold lower GPx level, when compared to its normotensive 
Wistar control (46975 ± 5242 vs 82567 ± 2537 GPx units/ml), and this difference was 
statistically significant (p<0.001). This trend was the opposite when the SHR-weanling was 
compared to the Wistar-weanling group, with the SHR-weanling group having a 2 fold higher 
GPx level than the Wistar-weanling (122839 ± 9225 vs 62189 ± 2476 GPx units/ml), and this 
difference was also statistically significant (p<0.001). When the SHR-adult was compared to 
the SHR-weanling group, the SHR-adult group had a 2.6 fold decrease in GPx levels, and this 
decrease was statistically significant (46975 ± 5242 vs 122839 ± 9225 GPx units/ml) 
(p<0.001). The Wistar-adult displayed an opposite trend with a 1.3 fold increase in GPx 
levels when compared to the Wistar-weanling (82567 ± 2537 vs 62189 ± 2476 GPx units/ml), 
and this increase was also statistically significant (p<0.05). 
The SHR-Ang II infused group had a 4.1 fold increase in GPx levels when compared to the 
saline infused control (180023 ± 3241 vs 43858 ± 3447 GPx units/ml), and this difference 
was statistically significant (p<0.001). The Wistar-Ang II infused group showed a 1.1 fold 
increase in GPx levels (87553 ± 3881 vs 81922 ± 3163 GPx units/ml), but this increase was 
not statistically significant (p>0.05). 
The degree to which the infusion of the sub-pressor dose of Ang II increased the GPx levels 
in the SHR and Wistar was compared, and the results show that in the Wistar infused with 
Ang II, the GPx levels were increased by 7%, but the SHR infused with Ang II showed a 






4.7. SERUM CATALASE 
Catalase was quantified in serum and the results are shown in Table 8 and represented in 
Figure 12. 
The results show that SHR group had a 1.6 fold higher level of serum catalase than the 
normotensive Wistar control (689.4 ± 48.3 vs 423.0 ± 45.6 Catalase units/ml), and this higher 
serum catalase level was statistically significant (p<0.01). The SHR-weanling had a 1.8 fold 
lower serum catalase than the Wistar-weanling (352.2 ± 26.3 vs 644.3±36.1 Catalase 
units/ml), and this difference in serum catalase levels was also statistically significant 
(p<0.001). When the serum catalase levels of the SHR-adult is compared to the SHR-
weanling, the SHR-adult had a 2 fold increase in serum catalase levels (689.4 ± 48.3 vs 352.2 
± 26.3 Catalase units/ml), and this difference was also statistically significant (p<0.001). The 
Wistar-adult showed an opposite trend with a 1.5 fold decrease in serum catalase levels 
(423.0 ± 45.6 vs 644.3 ± 36.1 Catalase units/ml), and this decrease in catalase levels was 
statistically significant (p<0.001). 
The SHR-Ang II infused group had a 1.3 fold decrease in the level of serum catalase when 
compared to the saline infused control (462.3 ± 47.8 vs 612.8 ± 36.3 Catalase units/ml), and 
this decrease was statistically significant (p<0.05). 
The Wistar-Ang II infused group showed an opposite trend in serum catalase levels when 
compared to the saline infused control, with the Wistar-Ang II infused group having a 1.8 
fold increase in serum catalase levels (987.3 ± 42.6 vs 556.3 ± 27.2 Catalase units/ml), and 
this difference in serum catalase was statistically significant (p<0.05). 
The degree of change caused by the infusion of Ang II with regards to the serum catalase 
levels in the SHR and Wistar was compared, and the results show that the sub-pressor dose of 
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Ang II decreased serum catalase levels in the SHR by 25%, and increased the serum catalase 























Table 8. Antioxidant Enzyme levels 
Statistical Analysis Comparison Key: 
* SHR   :Statistically significant difference when compared to the Wistar group 
* Wistar     :Statistically significant difference when compared to the Wistar-Weanling group  
*SHR-Weanling  :Statistically significant difference when compared to the SHR group 
* Wistar-Weanling :Statistically significant difference when compared to the SHR-Weanling  group 
*Wistar-Ang II :Statistically significant difference when compared to the Wistar-Saline infused group 
*SHR-Ang II  :Statistically significant difference when compared to the SHR-Saline infused group 



























(SOD units/ml) 69.3 ± 1.1* 61.5 ± 1.5* 49.6 ± 3.9* 51.0 ± 1.8 65.4 ± 4.2 
54.5 ± 2.6 
(17%) 70.2 ± 4.9 











2476* 81922 ± 3163 
87553 ± 3881 





(Catalase units/ml) 689.4 ± 48.3* 423.0 ± 45.6* 352.2 ± 26.3* 644.3 ± 36.1* 556.3 ± 27.2 
987.3 ± 42.6* 
(77%) 612.8 ± 36.3 




4.8. PLASMA HYDROGEN PEROXIDE 
Hydrogen peroxide (H2O2) levels were quantified in the plasma and the results are shown in 
Table 7 and represented in Figure 13. 
The results show that SHR group had a 1.4 fold higher plasma H2O2 level than the 
normotensive Wistar control (671.2 ± 52.7 vs 490.0 ± 46.0 ng/ml), and this higher plasma 
H2O2 level was statistically significant (p>0.05). The SHR-weanling had a 1.7 fold higher 
plasma H2O2 level than the Wistar-weanling (635.4 ± 41.5 vs 376.5 ± 20.6 ng/ml), and this 
difference in plasma H2O2 levels was also statistically significant (p<0.05). When the SHR-
adult group was compared to the SHR-weanling and the Wistar-adult to the Wistar-weanling 
group, there was no significant differences in the  plasma H2O2 levels of these groups (671.2 
± 52.7 vs 635.4 ± 41.5 ng/ml) and (490.0 ± 46.0 vs 376.5 ± 20.6 ng/ml) respectively. 
The SHR-Ang II infused group had a 1.4 fold decrease in plasma H2O2 when compared to the 
saline infused control (456.5 ± 38.1 vs 640.8 ± 21.6 ng/ml), and this decrease in plasma H2O2 
levels was statistically significant (p<0.05). 
The Wistar-Ang II infused group showed a similar trend with a 1.2 fold decrease in plasma 
H2O2 levels (425.0 ± 58.6 vs 499.0 ± 49.6 ng/ml), however this decrease was not statistically 
significant (p>0.05). 
The degree to which the infusion of the sub-pressor dose of Ang II decreased the plasma 
H2O2 levels in the SHR and Wistar was compared, and the results show that in the Wistar 
infused with Ang II, the plasma H2O2 levels were decreased by 15%, but the SHR infused 
with Ang II showed a greater degree of decrease, where the plasma H2O2 levels were 







4.9. KIDNEY F2-ISOPROSTANES 
F2-isoprostanes which is regarded as an indicator of in vivo lipid peroxidation was quantified 
in kidney tissue. The results are shown in Table 7 and represented in Figure 14. 
The results show that SHR group had a 1.3 fold higher level of F2-isoprostanes than the 
normotensive Wistar control (1.079 ± 0.047 vs 0.847 ± 0.041 ng/mg), and this increase was 
statistically significant (p<0.05). The SHR-weanling had a 1.3 fold higher F2-isoprostanes 
level than the Wistar-weanling (1.114 ± 0.039 vs 0.873 ± 0.043 ng/mg), this difference was 
also statistically significant (p>0.05). When the SHR-adult group was compared to the SHR-
weanling  group and the Wistar-adult to the Wistar-weanling group, there was no significant 
change in the plasma F2-isoprostane levels (1.079 ± 0.074 vs 1.114 ± 0.039 ng/mg) and 
(0.847 ± 0.041 vs 0.873 ± 0.043 ng/mg) respectively. 
The SHR-Ang II infused group showed no change in F2-isoprostane levels when compared to 
the saline infused control (0.998 ± 0.037 vs 1.003 ± 0.068 ng/mg). 
The Wistar-Ang II infused group showed a similar trend with no change in F2-isoprostane 












4.10. VASCULAR REMODELLING 
4.10.1. Aorta Media Wall Thickness 
The media wall thickness was measured in the aorta and the results are shown in Table 9 and 
represented in Figure 15. 
The results show that the SHR group had a 11.1% thicker tunica media than the normotensive 
Wistar control (100.3 ± 2.3 vs 90.3 ± 2.3 nm). This increase in thickness was statistically 
significant (p<0.05). The SHR-weanling showed a 6.5% thicker tunica media when compared 
to the Wistar-weanling (88.3 ± 2.3 vs 82.9 ± 1.7 nm), however this difference was not 
statistically significant (p>0.05). When the SHR-adult was compared to the SHR-weanling, 
the SHR- adult group showed a 13.6% increase in the tunica media thickness (100.3 ± 2.3 vs 
88.3 ± 2.3 nm), and this increase was statistically significant (p<0.05). The Wistar-adult 
group showed a 8.9% increase in media wall thickness, when compared to the Wistar-
weanling (90.3 ± 2.3 vs 82.9 ± 1.7 nm), and this difference was also statistically significant. 
(p<0.05) 
The SHR-Ang II infused group, showed no significant difference in the tunica media 
thickness of the aorta (106.6 ± 5.0 vs 105.0 ± 2.3 nm).   
The Wistar-Ang II infused group also showed no significant difference in the tunica media 










4.10.2. Aorta Wall to Lumen Ratio 
The wall to lumen ratio was assessed in the aorta and the results are shown in Table 9 and 
represented in Figure 16. 
The results show that the SHR group had a 24.3% greater W/L ratio than the normotensive 
Wistar control group (0.2396 ± 0.004 vs 0.1927 ± 0.005), and this difference in W/L ratio 
was statistically significant (p<0.05). The SHR-weanling had 46.7% greater W/L ratio than 
the Wistar-weanling (0.2749 ± 0.011 vs 0.1874 ± 0.005), this difference in W/L ratio was 
also statistically significant (p<0.05). When the SHR-adult was compared to the SHR-
weanling, the SHR-adult showed a 14.7% decrease in the W/L ratio, and this decrease was 
statistically significant (0.2396 ± 0.004 vs 0.2749 ± 0.011). The Wistar adult showed no 
significant change to the W/L ratio of the aorta when compared to the Wistar-weanling group 
(0.1927 ± 0.005 vs 0.1874 ± 0.005). 
The SHR-Ang II infused group, showed no significant difference in the W/L ratio of the aorta 
when compared to the saline infused control (0.2797 ± 0.013 vs 0.2713 ± 0.007).  
When the Wistar-Ang II infused group was compared to the Wistar-saline infused group, 
there was a 20.2% decrease in the W/L ratio (0.1649 ± 0.013 vs 0.2068 ± 0.008), and this 
decrease was statistically significant (p>0.05). 
The degree of change caused by the infusion of Ang II with regards to the W/L ratio of the 
aorta in the SHR and Wistar was compared, and the results show that the sub-pressor dose of 
Ang II did not change the W/L ratio of the aorta in the SHR, but decreased the W/L ratio of 








4.10.3. Iliac Artery Media Wall Thickness  
The media wall thickness was measured in the iliac artery and the results are shown in Table 
9 and represented in Figure 17. 
The results show that the SHR group had a 7.8% thicker tunica media than the normotensive 
Wistar control (77.8 ± 1.4 vs 72.2 ± 1.1 nm) and this greater thickness was statistically 
significant (p<0.05). The SHR-weanling showed a similar trend and had a 12.3% thicker 
tunica media than the Wistar-weanling (67.4 ± 4.4 vs 60.0 ± 2.8 nm), however this greater 
thickness was not statistically significant (p>0.05). When the SHR-adult was compared to the 
SHR-weanling, there was a 15.4% increase in the media wall thickness of the SHR-adult 
(77.8 ± 1.4 vs 67.4 ± 4.0 nm), and this increase was statistically significant (p<0.05). The 
Wistar-adult showed a 20.3% increase in wall thickness when compared to the Wistar-
weanling and this difference was statistically significant (72.2 ± 1.1 vs 60.0 ± 2.8 nm) 
(p<0.05). 
The SHR-Ang II infused group, showed an 8.8% increase in the tunica media thickness when 
compared to the SHR-saline infused group (86.6 ± 2.5 vs 79.3 ± 3.9 nm), however this 
increase was not statistically significant (p>0.05). 
The Wistar-Ang II infused group showed no significant change in the tunica media thickness 
when compared to the Wistar-saline infused group (65.4 ± 3.2 vs 67.0 ± 1.6 nm). 
The degree of change caused by the infusion of Ang II with regards to the media wall 
thickness of the iliac artery in the SHR and Wistar was compared, and the results show that 
the sub-pressor dose of Ang II increased the media wall thickness of the iliac artery in the 







4.10.4. Iliac Artery Wall to Lumen Ratio 
The wall to lumen ratio was assessed in the iliac artery and the results are shown in Table 9 
and represented in Figure 18. 
The results show that the SHR group had a 7.6% greater W/L ratio than the normotensive 
Wistar control group (0.2685 ± 0.0142 vs 0.2496 ± 0.0145), however this difference in W/L 
ratio was not statistically significant (p>0.05). The SHR-weanling had a 21.6% greater W/L 
ratio than the Wistar-weanling (0.2984 ± 0.0159 vs 0.2453 ± 0.0100), however this difference 
was also not statistically significant (p>0.05). When the SHR-adult was compared to the 
SHR-weanling, the SHR-adult had a 10.0% decrease in W/L ratio (0.2685 ± 0.0142 vs 0.2984 
± 0.159), this decrease was however also not statistically significant (p>0.05). When the 
Wistar adult was compared to the Wistar-weanling group there was no significant change in 
the W/L ratio of the iliac artery (0.2496 ± 0.0145 vs 0.2453 ± 0.100). 
The SHR-Ang II infused group, showed a 21% increase in W/L ratio when compared to the 
SHR-saline infused group (0.3194 ± 0.0153 vs 0.2641 ± 0.0137), and this increase was 
statistically significant (p<0.05).  
The Wistar-Ang II infused group was compared to the Wistar-saline infused group, and there 
was an opposite trend, with a 10% decrease in the W/L ratio (0.2191 ± 0.0122 vs 0.2436 ± 
0.0135), however this decrease was not statistically significant (p>0.05). 
The degree of change caused by the infusion of Ang II with regards to the W/L ratio of the 
iliac artery in the SHR and Wistar was compared, and the results show that the sub-pressor 
dose of Ang II increased the W/L ratio of the aorta in the SHR by 21%, but decreased the 



































Statistical Analysis Comparison Key: 
* SHR  :Statistically significant difference when compared to the Wistar group 
* Wistar     :Statistically significant difference when compared to the Wistar-Weanling group  
*SHR-Weanling  :Statistically significant difference when compared to the SHR group 
* Wistar-Weanling :Statistically significant difference when compared to the SHR-Weanling  group 
*Wistar-Ang II :Statistically significant difference when compared to the Wistar-Saline infused group 
*SHR-Ang II :Statistically significant difference when compared to the SHR-Saline infused group 
N.B. Red % – below the Wistar and SHR Ang II group values, means % increase ()/decrease() compared to the respective Saline infused control 

























100.3 ± 2.3* 90.3 ± 2.3* 88.3 ± 2.3* 82.9 ± 1.7 89.0 ± 4.6 90.5 ± 3.9 (0%) 105.0 ± 2.3 
106.6 ± 5.0 
(0%) 
Aorta: 




















































77.8 ± 1.4* 72.2 ± 1.1* 67.4 ± 4.0* 60.0 ± 2.8 67.0 ± 1.6 65.4 ± 3.2 (0%) 79.3 ± 3.9 
88.6 ± 2.5 
(12%) 
Iliac Artery: 
























































4.11. GENE EXPRESSION 
4.11.1. p22phox mRNA Expression 
Real-time PCR was used to quantify the p22phox mRNA in aorta tissue for all groups. 
p22phox gene expression data for each of the groups mRNA was normalized with GAPDH, 
by expressing data as a ratio of p22phox to GAPDH mRNA expression. The results are 
shown in Table 10 and represented in Figure 19. 
The SHR group showed a 3.24 fold lower p22phox mRNA expression when compared to the 
normotensive Wistar control (1.91 ± 0.28 vs 6.18 ± 0.58), and this difference was statistically 
significant (p>0.05). The SHR-adult showed a 4.73 fold decrease in p22phox expression 
when compared to the SHR-weanling (1.91 ± 0.28 vs 9.03 ± 0.58), and this decrease was also 
statistically significant (p<0.05). The SHR-weanling showed a 3.24 fold higher p22phox 
expression when compared to the Wistar-weanling group (9.03 ± 0.58 vs 2.79 ± 0.78), and 
this difference in p22phox expression was statistically significant (p<0.05). The Wistar-adult 
showed a 2.22 fold increase in p22phox mRNA expression when compared to the Wistar-
weanling (6.18 ± 0.58 vs 2.79 ± 0.78), and this increase was also statistically significant. 
(p<0.05) 
The SHR-Ang II infused group showed a 2.92 fold increase in p22phox expression when 
compared to the saline infused control (6.22 ± 0.90 vs 1.42 ± 0.10), and this increase was 
statistically significant (p>0.05).  
The Wistar-Ang II infused group showed a similar trend with a 2.27 fold increase in p22phox 
expression when compared to its saline infused control (14.61 ± 1.25 vs 5.75 ± 1.13), and this 
increase in expression was statistically significant (p<0.05).   
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The degree to which the infusion of the sub-pressor dose of Ang II increased the p22phox 
expression in the SHR and Wistar was compared, and the results show that in the Wistar 
infused with Ang II, the p22phox expression levels were increased by 154%, but the SHR 
infused with Ang II showed a greater degree of increase, where the p22phox expression 





















4.11.2. gp91phox mRNA Expression 
Real-time PCR was used to quantify gp91phox mRNA in aorta tissue for all groups. 
gp91phox gene expression data for each of the groups mRNA was normalized with GAPDH, 
by expressing data as a ratio of gp91phox to GAPDH mRNA expression. The results are 
shown in Table 10 and represented in Figure 20. 
The SHR group showed no difference in gp91phox mRNA expression when compared to the 
normotensive Wistar control (2.31 ± 0.26 vs 2.42 ± 0.72). This trend was repeated when the 
SHR-weanling was compared to the Wistar-weanling groups (3.70 ± 0.72 vs 2.98 ± 0.60). 
The SHR adult showed a 1.60 fold decrease in gp91phox expression when compared to the 
SHR-weanling (2.31 ± 0.26 vs 3.70 ± 0.72), however this decrease in expression was not 
statistically significant (p>0.05). The Wistar adult showed no significant difference in the 
expression of gp91phox when compared to the Wistar-weanling group (2.42 ± 0.72 vs 2.98 ± 
0.60). 
The SHR-Ang II infused group showed no difference in gp91phox expression when 
compared to the saline infused control (2.11 ± 0.30 vs 2.08 ± 0.19). The Wistar-Ang II 
infused group however showed a 1.86 fold decrease in gp91phox expression when compared 
to its saline infused control (1.71 ± 0.58 vs 3.18 ± 0.67), however this decrease in expression 










4.11.3. Cu/Zn SOD mRNA Expression 
Real-time PCR was used to quantify Cu/Zn-SOD mRNA in aorta tissue for all groups. 
Cu/Zn-SOD gene expression data for each of the groups mRNA was normalized with 
GAPDH, by expressing data as a ratio of Cu/Zn-SOD to GAPDH mRNA expression. The 
results are shown in Table 10 and represented in Figure 21. 
The SHR group showed no significant difference in Cu/Zn-SOD mRNA expression when 
compared to the normotensive Wistar control (2.93 ± 0.67 vs 2.38 ± 0.36). When the SHR-
weanling was compared to the Wistar-weanling the SHR-weanling showed a 6.60 fold higher 
Cu/Zn-SOD mRNA expression (45.04 ± 6.77 vs 6.82 ± 0.82), this difference in expression 
was statistically significant (p<0.001).The SHR-adult showed a 15.37 fold decrease in 
Cu/Zn-SOD expression when compared to the SHR-weanling (2.93 ± 0.67 vs 45.04 ± 6.77), 
and this difference in expression was statistically significant (p<0.001). The Wistar-adult 
showed a similar trend when compared to the Wistar-weanling group, with a 2.87 fold 
decrease in  Cu/Zn-SOD expression (2.38 ± 0.36 vs 6.82 ± 0.82), and this decrease was also 
statistically significant. (p<0.05) 
The SHR-Ang II infused group showed a 2.80 fold increase in Cu/Zn-SOD expression when 
compared to the saline infused control (9.12 ± 1.33 vs 3.26 ± 1.27), and this increase in 
expression was statistically significant (p<0.05).  
The Wistar-Ang II infused group showed an opposite trend with a 5.35 fold decrease in 
Cu/Zn-SOD expression when compared to its saline infused control (0.83 ± 0.25 vs 4.44 ± 
1.49), and this difference in expression was also statistically significant (p<0.05). 
The degree of change caused by the infusion of Ang II with regards to the Cu/Zn-SOD 
expression in the SHR and Wistar was compared, and the results show that the sub-pressor 
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dose of Ang II increased Cu/Zn-SOD expression in the SHR by 180%, but decreased the 























4.11.4. AT-1a mRNA Expression 
Real-time PCR was used to quantify AT-1a mRNA in aorta tissue for all groups. AT-1a gene 
expression data for each of the groups mRNA was normalized with GAPDH, by expressing 
data as a ratio of AT-1a to GAPDH mRNA expression. The results are shown in Table 10 and 
represented in Figure 22. 
The SHR group showed no significant difference in AT-1a mRNA expression when 
compared to the normotensive Wistar control (1.28 ± 0.14 vs 1.61 ± 0.29). When the SHR-
weanling was compared to the Wistar-weanling, the SHR-weanling showed a 4.42 fold 
higher AT-1a mRNA expression (15.15 ± 1.78 vs 3.36 ± 0.84), and this difference in AT-1a 
expression was statistically significant (p<0.001). The SHR-adult showed a 11.8 fold 
decrease in AT-1a mRNA expression when compared to the SHR-weanling (1.28 ± 0.14 vs 
15.15 ± 1.78), and this difference in expression was statistically significant (p<0.001). The 
Wistar-adult showed a 2.08 fold decrease in AT-1a mRNA expression when compared to the 
Wistar-weanling group, and this difference in expression was also statistically significant 
(1.61 ± 0.29 vs 3.36 ± 0.84) (p<0.05). 
The SHR-Ang II infused group showed a 3.98 fold increase in AT-1a expression when 
compared to the saline infused control (4.97 ± 0.84 vs 1.25 ± 0.54), and this increase in AT-
1a mRNA expression was statistically significant (p<0.05).  
The Wistar-Ang II infused group showed a similar trend with a 2.26 fold increase in AT-1a 
expression when compared to its saline infused control (9.77 ± 0.52 vs 4.33 ± 2.89), and this 
difference in expression was also statistically significant (p<0.05). 
The degree to which the infusion of the sub-pressor dose of Ang II increased the AT-1a  
expression in the SHR and Wistar was compared, and the results show that in the Wistar 
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infused with Ang II, the AT-1a mRNA expression levels were increased by 126%, but the 
SHR infused with Ang II showed a greater degree of increase, where the AT-1a mRNA 






















Table 10: Aorta mRNA Expression 
 
























1.28 ± 0.14 1.61 ± 0.29* 15.15 ± 1.78* 3.36 ± 0.84* 4.33 ± 2.89 
9.77 ± 0.52* 
(126%) 1.25 ± 0.54 





2.93 ± 0.67 2.38 ± 0.36* 45.04 ± 6.77* 6.82 ± 0.82* 4.44 ± 1.49 
0.83 ± 0.25* 
(81%) 3.26 ± 1.27 





2.31 ± 0.26 2.42 ± 0.72 3.70 ± 0.72 2.98 ± 0.60 3.18 ± 0.67 1.71 ± 0.58 (46%) 2.08 ± 0.19 






0.28* 6.18 ± 0.58* 9.03 ± 0.58* 2.79 ± 0.78* 5.75 ± 1.13 
14.61 ± 1.25* 
(154%) 1.42 ± 0.10 
6.22 ± 0.90* 
(338%) 
Statistical Analysis Comparison Key: 
* SHR   :Statistically significant difference when compared to the Wistar group 
* Wistar     :Statistically significant difference when compared to the Wistar-Weanling group  
*SHR-Weanling  :Statistically significant difference when compared to the SHR group 
* Wistar-Weanling :Statistically significant difference when compared to the SHR-Weanling  group 
*Wistar-Ang II :Statistically significant difference when compared to the Wistar-Saline infused group 
*SHR-Ang II  :Statistically significant difference when compared to the SHR-Saline infused group 
- Red % – below the Wistar and SHR Ang II group values, means % increase ()/decrease() compared to the respective Saline infused control 






This study has shown that the SHR, a well-established model of essential hypertension, 
demonstrates an evident link between Ang II and hypertension. Ang II has been shown to act 
as a causative factor in the pathogenesis of hypertension not only by its well established 
pressor effects, but also by its influence on the antioxidant and free radical systems via 
NADPH oxidase, resulting in a state of elevated oxidative stress in the model. This recently 
established mechanism although independent of other blood pressure elevating mechanisms 
in this model, works in parallel with them, resulting in the vicious cycle that is evident in 
hypertension. 
This has been demonstrated by the following pathophysiological changes in the SHR and the 
other experimental models used in this study (viz. the SHR - Ang II infused group and the 
Wistar - Ang II infused group): 
1. The SHR has an elevated circulating plasma Ang II level, and this increased level of 
Ang II plays a major role in elevating the blood pressure of the model via its 
previously reported pressor effects. 
2. The SHR has a compromised antioxidant status (on the basis of the levels of the major 
antioxidant enzymes viz. SOD, GPx, and catalase), as well as an increased level of 
free radical production. This results in the model being in a state of high level 
oxidative stress. This high level oxidative stress appears to be intimately linked with 
the hypertension in this model. 
3. A sub-pressor dose of Ang II administered to a normotensive rat model (i.e. the 
Wistar - Ang II infused group) over a four week period, elevated its blood pressure 
and also increased the activity of vascular NADPH oxidase. This increases the free 
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radical production in the vasculature and subsequently results in an overwhelmed 
antioxidant system. This results in the experimental model being in a state of high 
level oxidative stress. It is thus evident that there is a strong link between the 
increased oxidative stress and the elevation in blood pressure, with the Ang II being 
the causative factor in this link. 
4. A sub-pressor dose of Ang II administered to the SHR (i.e. the SHR - Ang II infused 
group) over a three week period, exacerbated the onset and level of the hypertension 
in this model and also increased the activity of vascular NADPH oxidase. 
Interestingly this infused model makes adjustments to the antioxidant system in 
response to an increase in NADPH oxidase activity that is not mirrored by the 
normotensive Ang II infused model. This demonstrates that in the SHR which is 
genetically predisposed to hypertension, the antioxidant system reacts differently to 
an added stressor (i.e. Ang II), than in the normotensive Wistar model.  
5. All experimental groups (i.e. the SHR, the SHR - Ang II infused group and the Wistar 
- Ang II infused group) showed changes to the vasculature, i.e. vascular remodelling, 
and these changes contribute to an increased peripheral resistance and/or decreased 
vascular compliance, and thus acts to elevate blood pressure. It is important to note 
that the vascular remodelling appears to precede the elevation in blood pressure in the 
SHR, and plays an important initiator and amplifier role in hypertension. It can thus 
be said to be a parallel blood pressure elevating mechanism, working in concert with 
the other established mechanisms to initiate, exacerbate and maintain the 
hypertension. 
6. The SHR showed an elevated level of kidney F2-isoprostanes, which is an in vivo 
marker for lipid peroxidation as well as a potent renal vasoconstrictor, thus these 
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elevated levels demonstrate an elevated level of tissue oxidative stress. The renal 
damage due to tissue oxidative stress has been reported to result in a reduction in the 
natriuretic and diuretic properties of the kidney which acts to decrease blood pressure, 
thus contributing to the elevation in blood pressure in this model. Furthermore the 
elevated F2-isoprostanes would result in an increase in renal vasoconstriction and this 
would further decrease the natriuretic and diuretic properties of the kidney, and thus 
elevate blood pressure  
Thus from the results it has been established that the SHR, has both a compromised 
antioxidant status and elevated free radical levels, resulting in the model being exposed to 
high level oxidative stress. Ang II has been shown to be a causative factor in this model via 
mechanisms other than that of its established pressor role, and these mechanisms are 
intimately linked with the antioxidant and free radical systems (and the consequent oxidative 
stress). This study has thus shown that these pathophysiological changes are linked to the 
hypertension that the SHR is predisposed to, as well as in the SHR – Ang II infused and the 
Wistar – Ang II infused groups, and that these parallel mechanisms will work in concert, 
leading to the vicious cycle that is evident in hypertension. These are the mechanisms that 
will be the focus of the discussion that follows. 
N.B. The table and flow diagram that follows is a summary of the link between Ang II and 













Ang II Infused 
Wistar 
Ang II Infused 
SOD   (10%) (17%) 
CuZn SOD 
(Aorta) - (180%) (81%) 
GPx  (7%) (310%) 
Catalase  (77%) (25%) 
p22phox 
(Aorta)  (338%) (154%) 
All values are shown as increase (), decrease () or no change (-) when compared to their 
respective controls.  
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5.1. BLOOD PRESSURE AND HEART RATE 
The SHR had a significantly higher systolic and diastolic blood pressure over the four 
successive weeks of the study when compared to the normotensive Wistar control. The SHR 
showed a steady increase in SBP from the first week till the end of study at four weeks. If one 
adopts the hypertension classification system provided by the WHO in the 2003 report as a 
means of comparison to evaluate the “extent” of the hypertension, then the SHR progresses 
from Grade 1 to the highest Grade 3, by the end of the final week of the study (WHO., 2003). 
The Wistar control on the other hand displayed a steady state normotensive systolic and 
diastolic blood pressure over the same time period. These results confirm the suitability of the 
genetically predisposed SHR and the normotensive Wistar controls to be excellent models for 
assessing and comparing the pathophysiological changes that occur in hypertension. 
The elevated blood pressure of the SHR becomes significant when one looks at the vascular 
remodelling (to be discussed in detail in Section 5.6), which is prevalent in this model. The 
SHR showed significant changes to the vasculature with a significantly thicker tunica media 
in both the aorta and the iliac artery. This increased thickness of the tunica media results in a 
greater W/L ratio in the aorta. The increase in W/L ratio, and the subsequent decrease in 
lumen diameter, will cause an increase in vascular resistance, and manifest as the elevated 
blood pressure that is shown in the SHR.   
The elevated blood pressure of the SHR also becomes significant when one looks at the 
plasma NO levels (to be discussed in detail in Section 5.4.2). This model had significantly 
lower plasma NO levels than the Wistar control. It is this compromised NO level, and the 
models subsequent reduced vasodilatory capacity, that contribute to and manifest as the 
elevated blood pressure in this model. 
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The SHR had a significantly higher heart rate than the Wistar control at the beginning of the 
study. These results are consistent with other studies that have shown the SHR to have a 
higher heart rate due to an increased level of sympathetic activity, which acts to increase the 
chronotrophic and inotrophic actions of the heart (Kirby et al., 1989). However, while the 
systolic and diastolic blood pressures increased over the successive weeks the heart rate 
showed a steady decrease. The Wistar model also showed a steady decrease in heart rate as 
the animal aged, with no change (i.e. increase or decrease) in blood pressure, thus the steady 
decrease in heart rate in the SHR and Wistar is age related. The SHR did however have a 
higher heart rate at the end of the study, and this is due to the increased sympathetic activity 
of this model. 
The SHR - Ang II infused group, showed significantly higher systolic and diastolic blood 
pressures from the beginning of the infusion till they were sacrificed at the end of the 3rd 
week, thus the infusion of the sub-pressor dose of Ang II over the 3 week period, exacerbated 
both the onset and the level of hypertension. The model reached high systolic and diastolic 
levels viz. 179 ± 2 mmHg and 116 ± 2 mmHg respectively by the end of the second week, as 
compared to the saline infused control only reaching this level in the fourth week (these 
levels are comparable with Grade 3 hypertension according to the WHO classification of 
2003). This therefore suggests that a long term infusion of a sub-pressor dose of Ang II is 
able to exacerbate the onset and level of hypertension in the SHR. Therefore, this 
experimental model would be useful in investigating the mechanisms by which the sub-
pressor dose of Ang II (viz. an increase in oxidative stress and its related blood pressure 
elevating mechanism) act to exacerbate the blood pressure in this model. 
The SHR - Ang II infused group showed no significant changes in the heart rate over the 
successive weeks of the study, however it did show a significantly higher heart rate at the end 
of the third week when compared to the saline infused control, and thus these results suggest 
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that Ang II has a positive chronotrophic effect. This is consistent with other studies that have 
shown that Ang II infusion increases the intrinsic heart rate, by affecting the baroreceptor 
reflex sensitivity, which inevitably causes an increase in heart rate (Machado and Salgado., 
1990). 
The Wistar Ang II infused model showed significant increases in blood pressure from the 
third week of infusion, and by the end of study, after four weeks these high levels in the 
systolic and diastolic blood pressure are comparable with the Grade 2 hypertension according 
to the WHO classification of 2003. This therefore shows that the sub-pressor dose of Ang II 
in the normotensive Wistar increases blood pressure slowly over a long period. This is 
consistent with other studies that have shown a similar increase in blood pressure due to the 
infusion of sub-pressor doses of Ang II (Simon et al., 1995). This therefore confirms the 
suitability of this model to investigate the long-term non-pressor role of Ang II that acts to 
elevate blood pressure.  
The heart rate of the Wistar - Ang II infused group was significantly lower in the second 
week of the infusion, demonstrating a possible compensatory change by the cardiovascular 
system to the increase in blood pressure caused by the Ang II. The heart rate then mirrored 
that of the saline infused control, suggesting a long term effect of Ang II to sustain the 
increased heart rate and provided further evidence that Ang II is a positive chronotrophic 
factor, which acts to increase the intrinsic heart rate, as mentioned previously by affecting the 






5.2. ANGIOTENSIN II, DOES IT UNDERLIE THE PATHOGENESIS OF 
HYPERTENSION? 
Angiotensin II levels were assessed in the plasma of all groups and the results show that the 
SHR had a significantly higher plasma Ang II level when compared to the Wistar control. 
The pathophysiological role that Ang II plays in hypertension is well established, and is 
usually attributed to its pressor effects i.e. its vasoconstrictor properties which act to increase 
total peripheral resistance, its stimulation of the thirst centre in the hypothalamus to increase 
fluid intake, its stimulatory role on aldosterone (which increases Na+ and H2O retention), and 
its stimulatory role on vasopressin (to prevent fluid loss in the urine). All of these factors act 
to essentially expand the plasma volume and thus increase blood pressure (Sealy and Laragh., 
1995). Thus an increase in circulating Ang II would result in an increase in blood pressure, by 
the above mentioned pressor effects, as well as the NADPH oxidase enzyme mechanism that 
is in question by this study. This therefore means that in the SHR the increase in blood 
pressure, is due in large part to the increase in circulating Ang II, as has been shown in 
previous studies (Bolterman et al., 2005). 
Although the SHR had higher plasma Ang II levels, the AT-1a mRNA expression in the aorta 
showed no difference in expression when compared to the normotensive control and this 
suggests no difference in AT-1a receptor expression/density (Suzuki et al., 1993), but the 
SHR still had a significantly higher blood pressure. The AT-1 receptor has been shown to 
mediate all the known functions of Ang II that act to elevate blood pressure, such as 
vasoconstriction, increased cardiac contractility, aldosterone release and, renal Na+ and H2O 
reabsorption  (Timmermans et al., 1993; Kim and Iwao., 2000). Thus these results show that 
the vasculature where the AT-1a mRNA expression was quantified viz. the aorta, is not a 
tissue that is a target for the increased circulating Ang II, to act to increase the blood pressure. 
These results are consistent with previous studies that have shown other target tissues which 
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include the kidney, heart, brain and smaller resistance vessels that show an increase in AT-1a 
mRNA expression, in the SHR and other models exposed to high circulating Ang II levels 
(Suzuki et al., 1993; Ito et al., 1995; Lenkei et al., 1997; Kim and Iwao et al., 2000). Thus 
without a change in the density of this receptor in the aorta, it confirms that the aorta, is not a 
target for Ang II in the SHR, but rather the other previously reported tissues, which play a 
major role via AT-1 in elevating the blood pressure.  
The link between Ang II and oxidative stress in hypertension, is an area that has received 
much attention in recent research, this being due to a mechanism by which Ang II increases 
blood pressure indirectly via the NADPH oxidase enzyme system. Ang II has been shown to 
stimulate O2- generation by increasing the activity of the enzyme; NADPH cytochrome P-450 
oxidoreductase, more commonly termed NADPH oxidase. This was demonstrated in cultured 
rat vascular smooth muscle cells and in intact aortas of rats made hypertensive by 
Angiotensin II infusion (Griendling et al., 1994; Zalba et al., 2001). However when rats were 
made hypertensive to a similar degree, by an infusion of noradrenalin, this model showed no 
increase in NADPH oxidase activity (Laursen., 1997). Interestingly, the blood pressure and 
vascular reactivity could be brought back to normal by exposure to an exogenous liposome-
encapsulated SOD in the Angiotensin II hypertensive rats, but not in the noradrenalin 
hypertensive rats (Griendling et al., 1994; Laursen., 1997; Zalba et al., 2001). The combined 
findings of these studies fortifies the causative role of O2- in hypertension that is associated 
with high Ang II states, and thus proves that elevated Ang II results in a state of increased in 
vivo oxidative stress. These studies concluded that Ang II – induced hypertension activates 
the NADPH oxidase system and increases O2- production and the increase in O2- is directly 
involved in the pathology of hypertension (Rajagopalan et al., 1996; McIntyre et al., 1999). 
The results of this study show that although the plasma Ang II levels of the SHR are elevated, 
the p22phox (a sub-unit of NADPH oxidase) mRNA expression in the aorta is not. This 
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finding is not consistent with the results of the previously mentioned studies where Ang II 
infusion and exposure increases p22phox mRNA expression. This is thought to be due to two 
main factors in this study, firstly although the SHR has elevated in vivo levels of Ang II, it is 
thought that the threshold for Ang II to increase/stimulate p22phox mRNA expression in the 
aorta, is greater than that which this model is exposed to at this age, thus there is no elevation 
of p22phox mRNA in the aorta. Secondly, the results indicate again that the aorta is not a 
target by Ang II in the SHR at this age as shown in previous studies and by the AT-1a mRNA 
expression results in this study. It is rather the smaller resistance vasculature that experience a 
higher shear stress. These vessels have been shown in this model to have an increased 
expression of the p22phox subunit of NADPH oxidase as well as an elevated level of O2- 
(Zalba et al., 2001), whereas the aorta shows elevated levels of p22phox expression, at a 
much later age (~30 weeks old), and this is thought to be linked to the elevated shear stress 
levels that the aorta is exposed to at that age (Zalba et al., 2000). 
When the SHR-adult is compared to the SHR-weanling, there was a significant age-related 
increase in plasma Ang II levels in the adult. This demonstrates that in the adult, Ang II 
production is increased. This increase is due to the reported increased activity of the renin-
angiotensin system (RAS) in this model as it ages (Matsushima et al., 1988). The AT-1a 
mRNA expression results show that the SHR-adult had a significant decrease in AT-1a 
mRNA expression in the aorta. This therefore suggests that this model has an age related 
decrease in AT-1a receptor density in the aorta and again suggests that the aorta is not a 
target tissue for Ang II to elevate the blood pressure in this model at this age. It is rather the 
previously reported tissues such as the kidney, heart, brain and smaller resistance vasculature 
(Suzuki et al., 1993; Ito et al., 1995; Lenkei et al., 1997; Kim and Iwao et al., 2000). The age 
related decrease is confirmed by the changes to the AT-1a mRNA expression and plasma 
Ang II results when the Wistar-adult is compared to the Wistar-weanling. The Wistar-adult 
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showed a significant decrease in plasma Ang II levels and a significant decrease in AT-1a 
mRNA expression, with no change in blood pressure. This confirms that the decrease in AT-
1a mRNA expression of the aorta in the SHR is age related, rather than pathological. These 
results therefore show that although the vasculature of the hypertensive and normotensive 
adults show an age related decrease in the receptor density of the AT-1a receptor in the aorta, 
the SHR, has a genetic predisposition to increased levels of circulating Ang II, via increased 
activity of the RAS system and the Wistar does not. Thus the elevated levels of Ang II are a 
contributing factor to the age related increase in blood pressure demonstrated by the SHR.  
The sub-pressor dose of Ang II (i.e. a dose of Ang II that has been shown to not elicit 
immediate pressor effects in the kidney and in the vasculature) infused into the SHR over 
three weeks, significantly decreased plasma Ang II levels (Simon et al., 1995). The infusion 
however exacerbated the onset and the level of hypertension displayed by this model, as 
demonstrated by the blood pressure results. The infusion of Ang II also significantly 
increased the AT-1a mRNA expression in the aorta, suggesting an increase in AT-1a receptor 
density. These changes show that an exogenous increase of Ang II via a sub-pressor dose in 
the SHR, results in a negative feedback inhibition of Ang II formation via RAS, and thus acts 
to reduce circulating plasma Ang II levels. Interestingly the AT-1a mRNA expression in the 
aorta is increased. This has also been demonstrated in other studies where an infusion of Ang 
II, resulted in a decrease in circulating Ang II levels, and it is this decreased circulating Ang 
II levels that is shown to cause an upregulation of AT-1 (Schiffrin et al., 1984). The 
upregulation of AT-1 will thus result in an increase in the Ang II mediated blood pressure 
elevating effects, even though the circulating levels are decreased. These results are 
consistent with other studies that have shown this negative feedback regulation of Ang II 
when circulating levels reach a threshold, and that the decreased Ang II levels subsequently 
enhance AT-1 receptor activation and activity (Douglas and Brown., 1982; Schiffrin et al., 
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1984; Lassegue et al., 1995; Nickenig and Harrison., 2002). Thus although the circulating 
Ang II levels decrease in the SHR by 71%, the AT-1a receptor density increases by 338%, 
and this will potentiate the effects of Ang II. The potentiation of Ang II effects as illustrated 
by the blood pressure results, manifests as an ‘accelerated’ onset and level of hypertension. 
The Wistar – Ang II infused group did not display the same trend and showed no significant 
change to the plasma Ang II levels. The group did however show a 126% increase in AT-1a 
mRNA expression. These results  thus confirm that a sub-pressor dose of Ang II would 
inhibit the RAS system, and prevent an increase in Ang II levels, but target cells (in this case 
the vasculature) become more sensitive by increasing their AT1-a receptor density and thus 
potentiating the effects of Ang II (Diep et al., 2002; Le et al., 2003). 
The results also show that a three week infusion of a sub-pressor dose of Ang II in the SHR 
decreases its Ang II levels to a greater extent than that in the Wistar. The greater inhibition of 
the RAS in the SHR, causes a greater degree of AT-1a upregulation, and thus the effect of 
this upregulation of AT-1a on the SHR will be more exaggerated. The results also indicate 
that the SHR, has a much higher threshold level for Ang II feedback inhibition, than the 
normotensive Wistar, and provides a reason for the higher “normal” circulating Ang II levels 
in the SHR.  
Thus these results show that an increased long term exposure to sub-pressor doses of Ang II, 
increases AT-1a receptor density in the vasculature and thus increasing Ang II’s blood 
pressure elevating properties. Other studies have shown that sub-pressor doses of Ang II, do 
not immediately increase blood pressure, but in the long term has slow pressor effects that 
work independently of the classic pressor mechanisms and significantly increase blood 
pressure (Romero and Reckelhoff., 1999). These mechanisms are still under investigation, 
but from this study it can be seen that Ang II increases AT-1a mRNA expression over the 
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long term, and thus the increase in receptor density would potentiate the blood pressure 



















5.3. NADPH OXIDASE, IS IT ANOTHER MECHANISM BY WHICH ANG II 
ELEVATES BLOOD PRESSURE? 
NADPH oxidase has been shown to be a major source of ROS in vascular cells. It consists of 
2 membrane bound subunits viz. p22phox and gp91phox, and 3 cytosolic subunits p67phox, 
p47phox and GTPase rac 1. Phagocytes, adventitial fibroblasts, vascular smooth muscle cells 
(VSMC) and endothelial cells (EC) contain this plasma-membrane bound multi-component 
oxidase that utilises electrons derived from NADPH to reduce molecular O2 to O2- (Stocker 
and Keaney., 2004).  
This study assessed the p22phox and gp91phox mRNA expression in the aorta and used the 
mRNA expression as a measure of the activity of the NADPH oxidase enzyme. The activity 
of NADPH oxidase was then used as an indirect measure of O2- production (Fukui et al., 
1997; Zalba et al., 2000; Laude et al., 2005). 
The gp91phox mRNA expression showed no significant changes amongst all groups in the 
study. The reason for this is similar to the findings of other studies that have shown that 
gp91phox is expressed as very low levels in VSMC’s, and at higher levels in EC’s and 
adventitial tissue (Zalba et al., 2001). The tissue where the mRNA expression was assessed 
viz. the intact aorta showed non-significant changes to gp91phox mRNA expression across 
all groups. The reason for this is due to the previously mentioned selective expression of 
gp91phox in EC’s. It is thought that in the handling and storage of the intact aorta segments, 
there was probable damage and loss of the endothelium and thus the EC’s. The loss of the 
endothelium thus resulted in the lack of gp91phox expression, and thus, gp91phox mRNA 
expression results will be excluded from the discussion. 
The p22phox subunit (which is largely expressed by VSMC’s) mRNA expression results 
show that the SHR had a significantly lower p22phox mRNA expression than the 
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normotensive Wistar control. These results would therefore suggest that the SHR had a lower 
O2- production. However previous studies have shown the SHR to have a higher O2- 
production/level (Boulemie et al., 1997). These results therefore suggest that the NADPH 
oxidase specifically in the aorta is not the main contributor to the increased O2- production in 
the SHR. This is especially so when taking into consideration the age of the group i.e. 8 
weeks old as discussed previously in Section 5.2. The reason as to why age needs to be 
considered, is that, these results are similar to results in a study by Zalba et al., (2001). The 
study showed that the SHR at 16 weeks of age, showed no difference in p22phox mRNA 
expression in the aorta, when compared to the normotensive controls but they did have higher 
O2- levels. However when 30 week old SHR’s in  the same study were compared to 30 week 
old normotensive controls, there was a significantly greater p22phox mRNA expression in 
the aorta. The results from that study therefore suggest that p22phox and thus NADPH 
oxidase in the aorta play a more pertinent role with respect to O2- production as the SHR ages 
and has long term exposure to an elevated blood pressure. The elevated blood pressure in this 
model is thought to be caused and maintained in part by the pressor effects of the increased 
Ang II viz. vasoconstriction of the smaller resistance vasculature and Na+   and H2O retention. 
Other studies have found that the SHR has a significantly higher level of O2- production than 
the normotensive control, and this is independent of age (Boulemie et al., 1997). Thus the 
results of this study combined with the reports of the other studies suggest that the source of 
the O2- is other than that of NADPH oxidase in the aorta, and is from smaller resistance 
vasculature, that experience higher/sustained shear stress, and this increased shear stress has 
been shown to increase the activity of NADPH oxidase (Zalba et al., 2001). Thus the age at 
which this group is at, the aorta is not exposed to a high enough levels of shear stress as 
compared to the older animals to increase the activity of NADPH oxidase. However when the 
shear stress is elevated, as demonstrated in the SHR - Ang II infused group, the p22phox 
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mRNA expression increases significantly. The Ang II results combined with the findings 
here, and of those in the previously mentioned  studies, show that the elevation in blood 
pressure in this model, is not caused by a single factor or agent, but rather a multitude of 
mechanisms that are working in concert to initiate and maintain an elevated blood pressure. 
This was demonstrated in studies whose findings show that the elevated ROS production 
occurs before the development of hypertension in the SHR, thus highlighting that the ROS, 
play a role in both the development and maintenance of hypertension in this model 
(Kitiyakara and Wilcox., 1998; Houston., 2005; Paravicini and Touyz., 2008). 
The Ang II infusion caused a significant increase in p22phox mRNA expression of both the 
SHR - Ang II infused group and the Wistar - Ang II infused group when compared to their 
respective saline infused controls. These results therefore suggest that the long term sub-
pressor dose of Ang II enhances specifically the p22phox subunit and therefore increases 
local O2- production i.e. by the vasculature, via the increased activity of NADPH oxidase. 
These results are consistent with other studies that have shown an increase NADPH oxidase 
activity in the vasculature due to stimulation by Ang II (Rajgopalan et al., 1996; Ushio-Fukai 
et al., 1996; Fukui et al., 1997). These results also demonstrate that the exacerbated increase 
in blood pressure (i.e. in the SHR – Ang II infused group), could be due to an increase in O2- 
production (mechanism to be discussed later in the role of O2- in hypertension – Section 
5.4.1) as well as the effects of the increased circulating Ang II (discussed in Section 5.2) and 
vascular remodelling (to be discussed in Section 5.6). This again demonstrates the multitude 
of mechanisms that are working in concert to initiate and maintain an elevation in blood 
pressure, in the SHR. 
Interestingly when the degree to which the infusion of the sub-pressor dose of Ang II 
increases p22phox expression in the SHR and Wistar is compared, it can be seen that in the 
Wistar, the p22phox expression increased by 154%, but in the SHR, the same sub-pressor 
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dose of Ang II increased p22phox expression by 338%. This therefore shows that the SHR 
has a greater sensitivity to Ang II stimulation and thus a greater capacity for ROS production 
and the resultant oxidative stress.  
These results demonstrate that Ang II has a significant localised effect on the vasculature to 
increase the production of O2- via its stimulation of NADPH oxidase. This brings the study to 
the point of now discussing how the organism attempts to neutralise O2- and the 















5.4. A COMPROMISED ANTIOXIDANT STATUS: IS IT THE CAUSE OR 
CONSEQUENCE OF AN ELEVATED BLOOD PRESSURE IN HYPERTENSION? 
The antioxidant status of all groups was evaluated by assessing the levels of the major 
antioxidant enzymes in the vascular compartment viz. SOD, GPx and Catalase. 
5.4.1. SOD THE PRIMARY DEFENCE AGAINST THE DELETERIOUS O2- 
RADICAL 
The results show that the SHR had a significantly higher SOD level than the normotensive 
control. SOD is the antioxidant enzyme that neutralises the deleterious reactive oxygen 
species, O2-, to a more stable and relatively less deleterious ROS H2O2. 
This greater SOD buffering capacity of the SHR is an adaptive mechanism that this 
genetically hypertensive rat model has developed to counter an increase in O2- production and 
minimise oxidative stress. The SHR has been shown in previous studies to have higher O2- 
levels than the normotensive control (Bouloumie et al., 1997). This adaptive trait is further 
reinforced by the H2O2 results, which show that the SHR had a significantly higher plasma 
H2O2 level than the normotensive control. Since SOD dismutates O2- to H2O2, an increase in 
SOD and O2- would result in an increase in H2O2 levels, which has been found in the SHR in 
this study. 
An increase in the SOD enzyme levels, should be indicative of a systemic increase in the 
mRNA expression of that enzyme as shown in previous studies viz. an increase in Cu/Zn 
SOD (Zelko et al., 2002), however the results of this study do not show this relationship. The 
reason for this is due to the Cu/Zn SOD mRNA expression being assessed in the vasculature 
(i.e. the aorta) and is indicative of cytosolic SOD (SOD-1) levels of the vascular cells that 
make up the aorta (mainly VSMC’s) and the SOD enzyme levels on the other hand were 
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assessed in the RBC and is indicative of RBC cytosolic SOD (SOD-1). The results thus show 
that differing cell types, within the same compartment express this enzyme at different levels. 
These levels of expression appear to be dependent on the cells production of and exposure to 
O2-, thus in the cells of the aorta, the O2- production is not elevated (this is confirmed by the 
p22phox mRNA expression results, which show this), and thus the cytosolic SOD, is 
therefore not elevated. Thus in the aorta of the SHR, there is normal O2- and SOD levels, and 
this is not indicative of the reported elevated levels of O2- that this model is exposed to 
(Bouloumie et al., 1997). Previous studies in this model, at this age, as discussed previously, 
have shown that the aorta, does not have an elevated level of O2- production via NADPH 
oxidase, and it is rather the smaller resistance vessels, exposed to a higher shear stress, that 
have elevated O2- levels via increased activity of NADPH oxidase (Fukui et al., 1999; Zalba 
et al., 2001; Faraci and Dideon., 2004). Thus it can be seen that in the SHR, it is these smaller 
resistance vessels that play a major role in contributing to the elevated levels of ROS and its 
related derangements that result in an elevation in blood pressure.  
When the SOD enzyme levels of the SHR-adult is compared to the SHR-weanling group, 
there is a significant increase in SOD levels in the SHR-adult, and this suggests that there is 
an age related increase in SOD, which is due to the reported age related increase in O2- 
production (Bouloumie et al., 1997). This previous study has shown that this increase in SOD 
in the adult is an adaptive mechanism to deal with higher levels of O2-. Interestingly the 
weanling had a significantly higher Cu/Zn SOD expression than the adult. This is also age 
related, and shows that as the model ages the vasculature decreases its antioxidant buffering 
capacity and production, and is thus more prone to oxidative stress, as demonstrated in the 
adult. This also shows that the adaptation of this major antioxidant (increase in SOD) is a 
response to the hypertension, and demonstrates an adaptive trait to deal with an elevated 
level/production of O2-. The Wistar showed a similar trend with regards to SOD, when 
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compared to the weanling and confirms that the changes in the SOD levels are age related. 
However the degree of decrease in Cu/Zn SOD is greater in the SHR than in the Wistar and 
suggests that this decrease in SOD buffering capacity would result in an increase in O2- in the 
vasculature and contribute to the elevation in blood pressure in this model. This also shows 
that the age related compensations are inadequate in the SHR which is exposed to higher 
levels of ROS than the Wistar, and thus the accumulation of these ROS play an important 
role in this model of genetic hypertension. 
The infusion of the sub-pressor dose of Ang II resulted in no significant change to the RBC 
(cytosolic) SOD levels in both the SHR and Wistar models, suggesting no change to the 
antioxidant buffering capacity of the RBC. However when looking at the Cu/Zn SOD mRNA 
expression i.e. the cytosolic SOD levels of the aorta the results show that the Ang II infusion 
resulted in a significant increase in the expression of this enzyme in the SHR. This suggests 
that there is an adaptive response to the significant increase in p22phox expression in the 
vasculature. Thus the increase in SOD would attempt to scavenge the increased O2- derived 
from NADPH oxidase and attempt to prevent the deleterious effects of O2- accumulation, and 
delay this process and its subsequent pathology. 
In the Wistar infused with the sub-pressor dose of Ang II there was an opposite trend with 
regards to the Cu/Zn SOD mRNA expression where the infusion resulted in a significant 
decrease in the expression of this important enzyme. This therefore suggests a decrease in the 
SOD antioxidant buffering capacity of the vasculature. The infusion also resulted in a 
significant increase in p22phox expression, and thus an increase in O2- production in the 
vasculature via NADPH oxidase. When considering both these results it suggests that in the 
Wistar – Ang II infused group there would be an accumulation of O2- in the vasculature, and 
this being due to both a decreased SOD antioxidant buffering capacity and an increased 
production of O2- via NADPH oxidase. These findings also suggest that Ang II inhibits 
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Cu/Zn SOD expression and stimulates NADPH oxidase activity and thus promotes the 
deleterious blood pressure elevating effects of O2- in the Wistar – Ang II infused model, and 
thus contributes to the increase in blood pressure demonstrated by this model. 
When the degree to which the infusion of the sub-pressor dose of Ang II changed the SOD 
antioxidant buffering capacity in the SHR and the Wistar is compared, the results show that 
the infusion had no significant effect on the RBC SOD i.e. the cytosolic SOD. However the 
infusion increased the expression of the Cu/Zn SOD in the vasculature of the SHR by 180%, 
but decreased the Cu/Zn SOD expression in the Wistar by 81%. This is significant when 
taking into consideration the changes to the p22phox expression, where the SHR showed a 
338% increase in p22phox expression and the Wistar showed a 154% increase in p22phox 
expression. This therefore suggests that although the SHR makes adjustments to the SOD 
antioxidant buffering capacity in response to the increase in O2- production via NADPH 
oxidase, the degree of O2- production is greater than the increase in SOD antioxidant 
buffering capacity and this would result in O2- accumulation. These results also suggest that 
the genetically hypertensive SHR has developed “protective” mechanisms with regards to the 
antioxidant system, that are not apparent in the normotensive model. These 
compensatory/protective/adaptive adjustments appear to stem from the SHR being 
genetically susceptible to elevated Ang II levels, and the Wistar not having this susceptibility. 
These findings are novel and more in-depth work on the exact mechanisms involved in this 
differential expression of this important antioxidant enzyme needs to be done to conclusively 
comment on these findings.  
The role that O2- plays in hypertension per se is a well-established and putative one. The most 
significant role is the interaction between O2- and nitric oxide (NO). NO is a potent 
endogenous vasodilator, it regulates vascular tone in normal vessels, which includes 
resistance vessels. It also causes renal vasodilatation with consequent diuresis and natriuresis. 
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The actions of NO would act to lower blood pressure and therefore a reduction in NO would 
result in a decrease in the vasodilatory capacity with a consequent elevation in blood pressure 
(McIntyre et al., 1999). 
O2- reduces the bioavailability of NO, due to its high affinity for NO. The combination of O2- 
and NO, results in the formation of peroxynitrite (ONOO-). Therefore conditions that 
promote O2- formation, such as in hypertension can be harmful in several ways. This being 
firstly by halting the beneficial effects of NO by reducing its bioavailability and secondly by 
the damaging effects of ONOO-. If ONOO- is protonated to peroxynitrous acid, the cleavage 
products are among the most reactive oxygen species, this includes the breakdown of 
arachidonic acid which results in F2-isoprostanes. The F2-isoprostanes have been shown to 
cause renal arteriolar vasoconstriction, in the biological system (Beckman et al., 1994; 
McIntyre et al., 1999). In addition to this, studies have demonstrated that O2- can act directly 
as a vasoconstrictor , as well as induce hypertrophy and proliferation of VSMC’s, resulting in 
irreversible changes to the vasculature i.e. vascular remodelling (Section 5.6) (Stocker and 
Keaney., 2004). 
The putative role that O2- plays during hypertension can be successfully assessed with 
reference to studies that have administered synthetic SOD to neutralise the O2- threat in 
hypertensive rats. The results of these studies were successful in lowering the blood pressure 
of these hypertensive rats (Nakazono et al., 1991). Thus the mechanism by which O2- acts on 
NO to increase blood pressure during hypertension is an important one. It can be further 
demonstrated how the deleterious effects of O2- are successfully neutralised by SOD and 
thereby lowering blood pressure, in studies linked with Down’s syndrome. The human gene 
for Cu/Zn SOD (SOD-1) has been localized to the 21q22.1 region of chromosome 21. 
Therefore, patients with Down’s syndrome (trisomy 21) have an extra copy of the gene and 
have been shown to have SOD-1 activity 50% greater than the normal diploid population, in 
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keeping with the gene-dosage effect (De la Torre  et al., 1996). Transgenic rats containing an 
extra copy of the human SOD-1 gene display some of the neurological defects characteristic 
of Down’s syndrome, including premature aging, suggesting that this gene is involved in the 
pathogenesis of Down’s syndrome (Yarom et al., 1988). The increased SOD-1 activity in 
Down’s syndrome may further indicate a role for O2- in hypertension. With a higher SOD-1 
activity, Down’s syndrome patients will have reduced O2- levels (McIntyre et al., 1999). If 
O2- excess is involved in the pathogenesis of hypertension, then one would expect Down’s 
syndrome patients to have a lower blood pressure, and this trend was shown to be the case in 
a study by Morrison et al., (1996). This thereby confirms the positive role that O2- plays in 
increasing blood pressure during hypertension by causing the effects discussed earlier. This 
adds further evidence to hypertension being classified as a disease that is intimately linked 
with an increased level of oxidative stress. 
As can be seen from these results, SOD depletion and increased O2- production, play an 
integral role in elevating the blood pressure in the SHR and in the experimental models, 
mainly due to the interaction between O2- and NO, and the next section will discuss the in 









5.4.2. NITRIC OXIDE: A VITAL “COG IN THE WHEEL” TO REDUCE BLOOD 
PRESSURE 
Nitric oxide levels were assessed in the plasma and the results show that the SHR had 
significantly lower plasma NO levels than the Wistar control. As discussed previously NO is 
a potent vasodilator and regulator of vascular tone, and thus plays an important role in blood 
vessels to decrease total peripheral resistance (TPR) and thus blood pressure. It is also known 
to increase renal vasodilation which increases natriuresis and diuresis, the result of which will 
tend to lower blood pressure. So the results indicate that the SHR has a decreased ability to 
reduce TPR and increase renal natriuresis and diuresis and ultimately decrease blood pressure 
(McIntyre et al., 1999). The decreased availability of NO in the SHR, manifests as the 
significant elevation in blood pressure demonstrated by this model. This elevation in blood 
pressure may be due to the models decreased vasodilatory capacity, and thus the subsequent 
increased vascular resistance. 
The reason for the decrease in NO, is due to the reported increase in O2- production by the 
SHR (Bouloumie et al., 1997; Zalba et al., 2001; Wassmann et al., 2004). O2- has a very high 
affinity for NO as discussed earlier, and thus with an increase in O2-, in the face of depleted 
SOD, this would result in an increase scavenging of NO by O2-, thus decreasing NO’s 
vasodilatory activity/capacity and contributing to an increase in blood pressure. 
When the SHR-adult is compared to the SHR-weanling, it can be seen that there is a 
significant age related decrease in NO levels. This trend was not apparent in the 
normotensive Wistar groups (i.e. adult vs weanling). Thus the decrease in NO can be 
attributed to the reported age related increase in O2- production of the SHR. This therefore 
contributes to the adult SHR’s decreased vasodilatory capacity and resultant elevated blood 
pressure. Studies have shown that the biological activity of NO is determined by the 
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availability of O2- (Zalba et al., 2001; Schnackenberg., 2002; Shimokawa and Matabo., 
2004). This therefore presents further evidence on the putative role played by NO depletion 
due to O2- in elevating blood pressure in hypertension. 
The Ang II infusion significantly decreased the NO levels in the SHR - Ang II infused group, 
and again this decrease can be attributed to the increase in O2- production via NADPH 
oxidase in the vasculature as demonstrated by the increase in p22phox mRNA expression 
results. The Wistar - Ang II infused group showed a similar trend with a decrease in NO 
levels. This decrease could also be attributed to an increased p22phox mRNA expression also 
seen in this model, which means an increase in O2- production by the vasculature. The 
decrease in NO in both these experimental models manifests as the significant increase in 
blood pressure noted in these models, which is due to the increased vascular resistance 
caused by the reduced vasodilatory capacity and subsequent vasoconstriction. 
When the degree to which the infusion of the sub-pressor dose of Ang II decreased NO levels 
in the SHR and Wistar are compared, the results show that in the SHR, the NO levels 
decreased by 36%, but in the Wistar the NO levels decreased by 12%. This can be attributed 
to the greater degree of O2- production in the SHR as compared to the Wistar. Thus the Ang 
II depletes NO indirectly via O2- to a greater extent in the SHR than in the Wistar, and thus 
decreases the vasodilatory capacity of the SHR more than that of the Wistar.  
The results of both these groups suggest that Ang II plays an important indirect role in 
modulating vascular tone. This is due to Ang II diminishing the vasodilatory capacity of the 
vessel wall by stimulating O2- production via the NADPH oxidase mechanism, and ultimately 
decreasing NO activity. This would result in an increase in vasoconstriction and subsequently 
vascular resistance and thus increases blood pressure.  
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5.4.3. GPX, CATALASE AND HYDROGEN PEROXIDE, DO THEY PLAY A ROLE 
IN THE PATHOGENESIS IF HYPERTENSION? 
GPx and Catalase are the antioxidant enzymes that neutralise H2O2 to H2O and O2. The SHR 
had a significantly lower GPx level than the normotensive control. This difference therefore 
suggests a decrease in the GPx antioxidant capacity of the SHR, to neutralise H2O2. This 
decrease in GPx antioxidant capacity will lead to subsequent H2O2 accumulation, evidence of 
this is provided by the plasma H2O2 results that show the SHR to have a significantly higher 
plasma H2O2 levels than the normotensive control. 
GPx levels however, cannot be viewed independently of catalase levels, as both these 
enzymes work in unison to neutralise H2O2 and prevent its accumulation. The catalase results 
show that the SHR had a significantly higher serum catalase level than the normotensive 
control. This is biologically significant and previous studies have shown that catalase 
becomes elevated and plays the chief role at high concentrations of H2O2, during high levels 
of oxidative stress and also during states of reduced GPx activity (Cai., 2005; Kirkman and 
Gaetani., 2006; Paravicini and Touyz., 2008). These results i.e. the catalase and H2O2 levels 
indicate that in the SHR the catalase levels are high due to the high levels of H2O2 and the 
reduced GPx activity, and this therefore suggests that the SHR is in a state of high level 
oxidative stress. This state of high level oxidative stress is due primarily to elevated levels of 
O2- and its subsequent dismutation by SOD discussed earlier and the elevated levels of H2O2 
discussed here. The same trend did not occur in the normotensive control, which had higher 
GPx levels, but lower catalase levels, which is due to the lower levels of H2O2, and thus 
would indicate that this model is not in a state of high level oxidative stress. The difference in 
trends of the genetically hypertensive and normotensive models, adds further evidence to link 
the hypertension demonstrated by the SHR to high level oxidative stress. 
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The source of the H2O2 can be attributed to the previously discussed results i.e. SOD levels 
and NADPH oxidase activity (p22phox mRNA expression). These results show that the 
increase in SOD levels in the SHR was due to an increase in O2- production, and this would 
lead to an increased dismutation of O2- to H2O2 and result in an increase in H2O2 levels and 
thus H2O2 accumulation, as the results show. This therefore demonstrates the integrated 
nature of the antioxidant system where an increase in SOD due to O2-, must also cause an 
increase in GPx and CAT to prevent oxidative stress via H2O2 accumulation. It is imperative 
that the antioxidant system functions in an integrated manner, thus minimizing oxidative 
stress and its associated pathological changes.  
When the SHR-adult is compared to the SHR-weanling, there was a significant decrease in 
the GPx levels in the adult, demonstrating that this model develops a reduced GPx activity as 
it ages. This characteristic exposes the SHR to increased levels of ROS and thus the SHR is 
unable to provide a resistance to oxidative stress via H2O2 accumulation. The Wistar adult 
does not mimic the same trait when compared to the Wistar-weanling, and instead shows a 
significant increase in GPx levels. This results in an increased GPx antioxidant buffering 
capacity, and is able to provide resistance to oxidative stress via H2O2. The Wistar adult also 
shows a significant decrease in CAT levels and thus demonstrates that the GPx system is able 
to cope with any increase in ROS that the Wistar might encounter as it ages. This importantly 
indicates that the model is not in any form of elevated oxidative stress. The SHR on the other 
hand is in a state of high level oxidative stress, this being due to the significant increase in 
CAT levels. Previous studies have shown that elevated levels of CAT are an indicator of high 
level oxidative stress (Kirkman and Gaetani., 2006). It can also be seen that although the 
CAT levels increase significantly, the H2O2 levels remain high. This would result in H2O2 
accumulation in the SHR and also indicates an increased H2O2 production as described 
earlier, this being due to the dismutation of O2- by SOD. 
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The Ang II infusion results show that there was a significant increase in GPx levels in the 
SHR - Ang II infused group when compared to the saline infused control. This therefore 
suggests that Ang II increases GPx levels. This is thought to be a compensatory response in 
an attempt to deal with the increase in H2O2 resulting from the increased dismutation of O2- 
by SOD discussed earlier. When analysing the H2O2 results, these results do not directly 
show this, as there was a significant decrease in H2O2 levels in the SHR - Ang II infused 
group. This therefore means that the significant increase in GPx levels is coping with the 
increased H2O2 production and actually decreasing H2O2 levels, and thus preventing the 
deleterious consequences of H2O2 accumulation. This is further confirmed by the significant 
decrease in CAT levels, which appear to decrease in response to the lower H2O2 levels. 
There is a contrast when looking at the Wistar - Ang II infused group, where there was no 
significant change in GPx levels, but a significant increase in catalase levels. These results 
firstly suggest that the Ang II infusion increases the activity of the catalase enzyme and 
secondly that the Wistar - Ang II infused group is being exposed to high levels of H2O2. 
However the increased CAT compensation is sufficient to neutralise the H2O2 levels and 
bring them down to below normal and prevent H2O2 accumulation. Although the H2O2 levels 
in the Wistar - Ang II infused group show no significant change to the control, this could be 
due to the increase in catalase that lowers H2O2 levels and attempts to prevent H2O2 
accumulation. As discussed previously the p22phox mRNA expression results suggests a 
significant increase in O2- production via the NADPH oxidase mechanism and thus an 
increase H2O2 production via O2- dismutation by SOD, but the increase in CAT in response to 
Ang II appears to be preventing an accumulation of H2O2. 
When the degree to which the infusion of the sub-pressor dose of Ang II affected the GPx, 
CAT and H2O2 levels in the SHR and the Wistar are compared, the results show that in the 
SHR, the infusion increased GPx levels by 310%, but had no significant effect on the Wistar. 
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This therefore suggests that the genetic susceptibility of the SHR to high Ang II levels, allows 
the SHR and not the Wistar to make compensatory adjustments to the GPx system. This 
adjustment minimises a further increase in the high level of oxidative stress experienced by 
this model, and also attempts to prevent H2O2 accumulation.  
When looking at the CAT results, the infusion of the sub-pressor dose of Ang II significantly 
decreased the CAT levels in the SHR by 25%, but in the Wistar, the CAT levels were 
increased by 77%. This therefore suggests that the Wistar is in a state of high level oxidative 
stress, while the SHR is maintaining and actually attempting to reduce its “normal” high level 
oxidative stress. Thus the genetic susceptibility of the SHR to high levels of Ang II and 
oxidative stress appear to have equipped this model with mechanisms to prevent a further 
increase in H2O2 accumulation. Interestingly the comparative GPx and CAT results show that 
in the SHR which has a genetic susceptibility to high Ang II levels, the GPx is the first line of 
resistance to an increased oxidative stress by H2O2 accumulation. However in the Wistar 
which lacks this genetic susceptibility to high Ang II levels, the CAT system is the first line 
of resistance to the increased oxidative stress by H2O2 accumulation. 
The consequences of exposure to increased levels of H2O2 are deleterious, and the prevention 
of H2O2 accumulation is imperative in maintaining homeostatic balance. Virtually all types of 
vascular cells produce O2- and H2O2. The endothelium plays a fundamental role in the 
regulation of vascular tone and vascular remodelling. Exposure of the EC’s (endothelial cells) 
to O2- and H2O2 has been shown to induce the deleterious process of apoptosis (programmed 
cell death), this process essentially leads to EC loss and results in atherogenesis and a 
procoagulative state (McIntyre et al., 1999; Dimmeler and Zeiher., 2000; Taniyama and 
Griendling., 2003). These reactive oxygen species (ROS) regulate apoptotic mechanisms 
induced by a variety of stimuli. Another type of programmed cell death, termed anoikis, 
results from the detachment of EC’s from the extracellular matrix and this process is also 
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associated with increased intracellular ROS (Li et al., 1999; Taniyama and Griendling., 
2003). 
The production of ROS O2- and H2O2 are involved in many of the processes leading to both 
hypertrophic and proliferative vascular smooth muscle cell (VSMC) growth. These ROS also 
mediate the full proliferative response to agonists such as platelet derived growth factor 
(PDGF) and thrombin. H2O2 itself induces VSMC proliferation, although this effect appears 
to be critically dependant on the concentration of H2O2 which cells are exposed to. It has 
been found that endogenously produced H2O2 may also be important in modulating survival 
and proliferation of VSMC’s (Taniyama and Griendling., 2003). 
It has been shown previously, that relatively high concentrations of H2O2 induce apoptosis, 
whereas a moderate concentration causes cell cycle arrest, this therefore demonstrates that 
concentrations of H2O2 from moderate to high, have deleterious effects in the vasculature 
(Taniyama and Griendling., 2003). H2O2 does not function as a mitogen for VSMC’s, instead, 
it serves as a stimulus to trigger VSMC apoptosis (Li et al., 1997). These factors suggest that 
H2O2 contributes to hypertension by altering vascular remodelling. Structural vascular 
remodelling is a hallmark of chronic hypertension, and an increased wall to lumen ratio of 
resistance arteries is the predominant lesion. The increase in relative “thickness” of resistance 
arteries is responsible for the “amplifier” property of the arterial circulation in hypertension, 
which functionally manifests itself as a pressor or vasoconstrictor hyper-responsiveness 
(Simon et al., 1998). 
An accumulation of H2O2 in vivo, could have the following deleterious effect if not 
neutralised by GPx and CAT. In the presence of the transition metals Iron (Fe2+) and Copper 
(Cu2+), H2O2 is broken down to the hydroxyl radical (OH-), which is considered to be 
potentially the most potent oxidant encountered in biological systems (Yu., 1994). The OH- 
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radical causes strand breaks and base modification in DNA leading to changes in gene 
expression, mutation and apoptosis. Protein side chains are oxidised which can result in 
enzyme, receptor and carrier dysfunction. The resulting lipid peroxidation due to OH- alters 
functional properties of membranes and delivery of lipids to tissues and ultimately decreases 
cellular integrity and functioning (Halliwell., 1996). 
Thus an elevated level of H2O2 in the face of depressed GPx and CAT will cause an 
accumulation of H2O2 and thus would result in the formation of OH-. OH- has been reported 
to cause an increase in lipid peroxidation resulting in tissue damage associated with the 
hypertensive state. Thus increased levels of H2O2 contribute to hypertension via two main 
mechanisms, firstly via vascular remodelling and secondly by the formation of OH-, leading 
to lipid peroxidation and eventual tissue/end-organ damage. 
Oxidative stress leading to tissue damage, appears to be a focal point in hypertension 
research. The resultant tissue damage associated with lipid peroxidation is considered to be a 
major factor in the pathogenesis of hypertension. Empirical evidence has also shown that the 
architectural changes that are induced during oxidative stress in the kidney, heart and blood 








5.4.4. IS THE ANTIOXIDANT STATUS OF THE EXPERIMENTAL GROUPS 
COMPROMISED? 
From the results discussed above, it can be seen that the experimental groups viz. the SHR, 
the SHR - Ang II infused group and the Wistar - Ang II infused groups have a compromised 
antioxidant status. This is primarily due to the dysfunctional levels of the primary antioxidant 
enzymes. Although the system attempts to make compensatory adjustments to some of these 
enzymes, these adjustments appear to be insufficient to deal with the increased levels of the 
ROS. This leads to these experimental models/groups being in a state of high level oxidative 
stress. The antioxidant status of these groups appear to be both the cause and the consequence 
of the oxidative stress. This being due to either the reduced antioxidant capacity, or to the 
deleterious increase in free radical generation during hypertension. It can thus be seen from 
the results of this study that in the hypertension in these models, there is an evident link with 
high level oxidative stress, where the consequences of a dysfunctional antioxidant system are 
highlighted. The dysfunctional nature of the antioxidant system shown here that is due to 
and/or resulting in oxidative stress, has also been shown in previous studies in humans, and 









5.5. TISSUE OXIDATIVE STRESS: IS THE KIDNEY A TARGET FOR REACTIVE 
OXYGEN SPECIES IN HYPERTENSION? 
Tissue oxidative stress with resultant lipid peroxidation was assessed in the kidney, using a 
reliable indicator of in vivo lipid peroxidation viz. F2-isoprostanes. The reason for the kidney 
being used to assess tissue damage via lipid peroxidation, was due to previous studies that 
have shown the kidney to be a target organ for tissue oxidative stress, and also because of the 
important homeostatic role played by the kidney in blood pressure regulation (Badr and Abi-
Antoun., 2005). 
The results show that the kidney of the SHR had a significantly higher level of F2-
isoprostanes than the normotensive control. This therefore suggests an increase in the level of 
in vivo lipid peroxidation and thus an increased threat to the structural and functional integrity 
of the organ. The increased level of lipid peroxidation in the SHR could be due to the 
previously discussed results that suggest the SHR to have a higher level of ROS that cause 
lipid peroxidation and also a compromised level of antioxidant enzymes that would act to 
prevent lipid peroxidation (Chabrashvili et al., 2002). The accumulation of the ROS’s, 
especially the elevated levels of H2O2 and the increase in OONO-, could be the causative 
factors for the increased lipid peroxidation and the F2-isoprostane formation (Paravicini and 
Touyz., 2008). 
The lipid peroxidative damage will result in impaired renal functioning and contribute to an 
increase in blood pressure by reducing the natriuretic and diuretic properties of the kidney. 
Also the F2-isoprostanes, which as previously stated are products of the lipid peroxidative 
breakdown of arachidonic acid by OH- and OONO-, have been shown to be potent renal 
vasoconstrictors. Renal vasoconstriction would result in a decrease in glomerular filtration 
and would thus further decrease the natriuretic and diuretic properties of the kidney. Thus 
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both of these mechanisms would contribute to an elevation in blood pressure. Interestingly 
studies have shown that the increased renal expression of NADPH oxidase subunits (a source 
of ROS in the kidney) precedes the development of hypertension. Thus, increased expression 
of NADPH oxidase and the consequent increase in ROS production resulting in increased 
tissue oxidative stress appears to be one of the causative factors in, rather than a consequence 
of hypertension (Chabrashvili et al., 2002; Wilcox., 2002). 
The Ang II infusion models i.e. the SHR - Ang II infused group and the Wistar - Ang II 
infused group, showed no significant difference in their kidney F2-isoprostane levels when 
compared to their relative controls, and thus did not show an increased  level of lipid 
peroxidation. Although these groups showed an increased level of oxidative stress, due to 
increased ROS production, they did not show significant increases in lipid peroxidation in the 
kidney. This could perhaps be due to the fact that the experimental period of four weeks was 
not sufficiently long enough for changes in this parameter. Also from the results the 
compensatory increases in GPx and CAT, suggest that the changes to these important 
antioxidant enzymes, successfully prevented H2O2 accumulation by neutralising this threat, 
and thus preventing an increase in lipid peroxidative damage to the kidney. 
This adds further evidence that the increase in blood pressure in these models are independent 
of the Ang II pressor effects on the kidney, and thus shows that the O2- role via NADPH 
oxidase on the vasculature is one of the primary short-term mechanisms of blood pressure 






5.6. VASCULAR REMODELLING: AN AMPLIFIER AGENT IN HYPERTENSION 
Vascular remodelling refers to the architectural changes that occur in the blood vessel. It is 
characterised by an increase or decrease in the thickness of the tunica media (i.e. due to 
proliferation and hypertrophy of the VSMC’s), with a resultant change in the wall to lumen 
ratio (W/L ratio). An increase in the W/L ratio signifies an increase in the thickness of the 
media and a consequent decrease in lumen diameter. A decrease in the W/L ratio signifies a 
decrease in media thickness and a consequent increase in lumen diameter. Both these 
characteristic changes to the blood vessel have profound effects on the patency of the blood 
vessel by adversely affecting vascular tone. They either increase vascular resistance (by 
decreasing the lumen diameter, and thus increasing resistance to blood flow, resulting in an 
increase in blood pressure), or decreasing vascular elasticity/compliance contributing to ‘stiff 
vessels’ or less compliant vessels (these vessels are unable to adjust to or accommodate an 
elevation in blood pressure, thus acting as an amplifier to the elevated blood pressure) 
(Mulvany., 1999). 
Vascular remodelling was assessed in 2 major blood vessels viz. a portion of the aorta and a 
portion of the iliac artery. The results show that the SHR had a significantly thicker tunica 
media (in both the aorta and the iliac artery), than the normotensive control, this therefore 
suggests increased hypertrophy of the VSMC’s. This is due to the higher plasma H2O2 levels 
displayed by the SHR as H2O2 has been shown by previous studies to increase VSMC’s 
hypertrophy/proliferation (Li et al., 1997; Brown et al., 1999; Laurent et al., 2001; Taniyama 
and Griendling., 2003). The source of the the H2O2 has been shown by previous studies and 
demonstrated in this study to be derived from O2- produced by the NADPH oxidase system, 
and the subsequent dismutation of this O2- by SOD. This therefore supports the concept that 
both O2- and H2O2 whose production is stimulated by Ang II are growth promoting and 
hypertrophic factors and that their existence is mutually dependent (Zafari et al., 1998). 
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The increase in the thickness of the tunica media of the SHR manifests as a significantly 
greater W/L ratio in the aorta with no significant difference in total cross sectional area of the 
vessel, suggesting a smaller lumen diameter. According to the model provided by Mulvany, 
(1999) which has been adopted by this study, this can be classed as eutrophic inward 
remodelling. This type of remodelling would therefore result in an increase in vascular 
resistance and manifests as the significant increase in blood pressure that is shown by this 
model, as discussed previously.  The significantly greater W/L ratio in the genetically 
hypertensive strain as compared to the normotensive strain is consistent with previous studies 
in these models. This suggests that the differences are due to the genetic predisposition of the 
model to an increased blood pressure and shear stress exposure, and are thus one of the initial 
contributing factors to the elevation in blood pressure of the SHR (Auch-Schwelk., 1989; 
Mulvany et al., 1996; Taniyama and Griendling., 2003). This is further supported by the 
SHR-weanling which had a significantly greater W/L ratio than the normotensive-weanling, 
with no significant difference in the thickness of the tunica media and a significantly smaller 
total cross sectional area (meaning a smaller vessel size at the same age). This demonstrates 
the genetically predisposed nature of this model to an increased peripheral resistance. This 
shows that the vascular remodelling is an early etiological factor that even precedes the 
elevation in blood pressure in the SHR and is thus an important initiatory contributor to the 
hypertension in the SHR. 
The Wistar - Ang II infused group showed no significant changes in the tunica media 
thickness of the aorta, but a significant decrease in the W/L ratio with no significant change 
to the total cross sectional area. Interestingly this was not mirrored by the smaller iliac artery. 
This type of remodelling can be classed as eutrophic outward remodelling, and suggests an 
adjustment by this portion of the vasculature to compensate for the increased blood pressure 
and shear stress. It would be expected, that the vessel wall would increase in thickness, due to 
160 
 
the hypertrophic and inflammatory stimulation of the VSMC’s, by Ang II and H2O2, as 
shown in previous studies (Griendling and Ushio-Fukai., 2000), but this is not evident here, 
and this finding requires further investigation.  
The SHR - Ang II infused group, showed no significant change in the thickness of the media 
wall of both the aorta and the iliac artery, however there was a significant increase in the W/L 
ratio of the iliac artery. This increase in W/L ratio is due to the increase in the media wall 
thickness of the iliac artery. This change in the iliac artery can be classed as eutrophic inward 
remodelling due to there being no significant change in the total cross sectional area of the 
vessel. This suggests hypertrophy of the VSMC’s due to Ang II and H2O2, resulting in a 
decrease in lumen diameter (Griendling and Ushio-Fukai., 2000). This decrease would result 
in an increased vascular resistance, and an increase in blood pressure. This decrease in lumen 
diameter is supported by the significant elevation in blood pressure shown in this model. 
Vascular remodelling is the hallmark of essential hypertension, and acts to increase vascular 
resistance and thus exacerbates the elevation of blood pressure in the condition. It can thus be 
seen that the vasculature, plays an important hemodynamic role in hypertension, in the SHR 
and that these changes precedes the elevation in blood pressure. Over time, more changes to 
the vasculature dictated by factors such as Ang II and ROS amongst others, compounds and 
becomes maladaptive, and contributes via a mechanism that works in concert (i.e. increased 







6. CONCLUSION AND RECOMMENDATIONS 
This study has provided further evidence that the SHR is an excellent model for assessing the 
pathophysiological changes that are associated with essential hypertension. It has shown that 
the SHR has an increased level of oxidative stress, due to the reported O2- and H2O2 
accumulation. Although the SHR responds to the oxidative stress by making compensatory 
adjustments to the major antioxidant enzymes viz. SOD, GPx, and catalase, these adjustments 
appear to be inadequate to deal with the increased free radical generating capacity of the 
model, resulting in a state of high level oxidative stress. This is confirmed by the H2O2 
accumulation displayed in the model. This suggests that H2O2 accumulation and its resultant 
deleterious effects such as increased lipid peroxidation and vascular remodelling are some of 
the many independent mechanisms that are working together to contribute to the vicious 
cycle that is the hallmark of essential hypertension. This is further evidence to the accepted 
norm that essential hypertension is a multi-factorial disease condition.  
Future studies should consider quantifying the plasma O2- levels directly. There are two 
reasons as to why this study did not do this, the first was primarily due to the protocol and 
equipment required for the analysis, and this was beyond the infrastructural capabilities of 
our laboratory and the second reason was due to the cost of the analysis. A direct measure of 
O2- combined with the NO and OONO- levels would be an excellent measure of the exact in 
vivo relationship of these important causative factors in essential hypertension in these 
models. 
Another recommendation would be to assess the plasma SOD (ecSOD/SOD-3) levels rather 
than the RBC SOD (cytosolic Cu/Zn SOD – SOD-1) levels, as the antioxidant and free 
radical system is cell and compartment specific, and this would have been a better indicator 
of the level of this essential antioxidant enzyme. It will also be interesting to compare the 
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different compartments and how they react in this model to counter the established increased 
activity of the ROS, in specific compartments. This would enable one to demonstrate whether 
oxidative stress is compartment specific, and it can thus be shown whether; during oxidative 
stress in hypertension, specific compartments are targeted and affected.  
Apart from the free radical related changes, NO appears to be a main target for the O2-. The 
deficiency of this important vasodilator, is thought to initially contribute to and thus 
essentially responsible for the elevation in blood pressure/decreased ability to reduce blood 
pressure in this model. The diminished NO levels compounded with the vascular remodelling 
noted in the model, due to the effects of the free radicals (especially O2- and H2O2 which 
causes VSMC’s hypertrophy and proliferation respectively), add strong evidence of the link 
between oxidative stress and hypertension in the SHR. The free radicals are shown to bring 
about slow pressor changes, especially an increase in vascular resistance, and thus the ROS 
can be classed as long term pressor agents/factors. 
The role of Ang II in hypertension has been actively researched and is hence well 
documented. This study has added further evidence to strengthen the hypothesis that Ang II 
derangement is deleterious with regards to its blood pressure elevating properties. The 
statement/idea that essential hypertension is intimately linked with oxidative stress is further 
strengthened by the role established in other studies and fortified in this study i.e. Ang II 
directly increases the production of free radicals, by stimulating the activity of the NADPH 
oxidase enzyme. The resultant oxidative stress potentiates other mechanisms that thereafter 
work in parallel with the classic pressor mechanisms of Ang II, to elevate blood pressure. 
This study has also concluded that the SHR has a genetic predisposition to an increase in 
blood pressure due to an increased capacity to produce free radicals, and that this free radical 
production precedes the increase in blood pressure. This was deduced by comparing the adult 
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model to the weanling model, thus implicating the increase in the free radical generating 
capacity as being one of the possible causative factors in the elevation of blood pressure in 
this model. This study has also shown that vascular remodelling precedes the elevation in 
blood pressure in the SHR. These results fortifies the notion of the multifactorial nature of 
essential hypertension and provides justification for the call of therapeutic intervention in 
those who are predisposed to hypertension.  
This study has also shown that sub-pressor doses of Ang II administered to a normotensive 
model (i.e. Wistar - Ang II infused group), causes an elevation in blood pressure, via the 
activation of the NADPH oxidase enzyme. The activation of this system has been shown to 
increase O2- production in the vasculature. This occurs concomitantly with a decrease in 
VSMC production of SOD. This results in specific derangements viz. decrease in NO 
bioavailability, increase in VSMC hypertrophy (vascular remodelling) and vasoconstriction, 
thus resulting in an elevation of blood pressure. Thus, by using a sub-pressor dose this study 
has provided evidence of an independent mechanism that acts to elevate blood pressure. 
The SHR - Ang II infused group, further strengthened the hypothesis that the hypertension 
displayed in this model is intimately linked with oxidative stress. Interestingly with the added 
hypertensive stress of the sub-pressor doses of Ang II, the antioxidant system makes 
significant adjustments to counter the increase in free radical production; however these 
adjustments seem to be overwhelmed by the concomitant increase in free radical production. 
The Ang II infusion has shown that specific tissues become more receptive to the actions of 
Ang II when exposed to increased concentrations of the peptide, this is apparent from the AT-
1a receptor expression, which showed significant increases in the infused groups. This 
suggests that Ang II displays a positive feedback with regards to the receptors, and thus 
potentiating its blood pressure elevating effect.  
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A recommendation would be to remove the exogenous source of Ang II after a period of 
infusion and then analyse the model after the Ang II levels have returned to normal in vivo 
levels. This is to determine whether the AT-1a receptor expression recovers to normal or 
whether they are maintained at the infused level. This would demonstrate whether exposure 
to increased levels of Ang II sensitises target tissue for a longer period than is necessary, thus 
increasing the blood pressure for longer than is required for homeostatic regulation. This is a 
very promising aspect of the study that needs to be further investigated, as a previous study 
demonstrated that models who have been exposed to exogenous sources of Ang II, to induce 
hypertension, become salt sensitive when the exogenous source has been removed and Ang II 
levels return to normal (Lombardie et al., 1999). This thereby confirms that chronic/acute 
exposure to increased levels of Ang II in vivo causes long term derangements to the 
organs/systems responsible for regulating blood pressure. Thus the use of selective doses of 
Angiotensin II antagonists (AT 1 blockers) may play an important role to counter the 
sensitisation of target tissues. 
This study has also concluded that the kidney of the SHR is a target organ for oxidative stress 
in essential hypertension. Although it is not necessarily the primary cause of the elevated 
blood pressure, the oxidative stress related damage and derangement contribute to decrease 
the kidneys natriuretic and diuretic role which would act to lower blood pressure. It can thus 
be said that the kidney is both a causative factor and a consequent victim of this free radical 
related disease.  
A recommendation for future studies would be to compare different tissues involved in blood 
pressure control and regulation, and the tissue oxidative stress levels of these tissues to assess 
whether the free radical ‘attack’ is specific or indiscriminate. This would provide important 
information to help protect specific tissues/organs to decrease the derangement caused by the 
free radicals.  
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Another recommendation would be to assess the level of oxidative stress continuously over 
the entire study period by assessing the F2-isoprostane levels in the urine. This would 
determine whether the lipid peroxidation increases with increasing blood pressure or whether 
the level remains constantly high during essential hypertension and thus attempt to correlate 
the rise in blood pressure and the level of in vivo oxidative stress. 
The study has also concluded that vascular remodelling plays an important amplifier role in 
hypertension. It has also shown that the architectural changes in the vasculature precedes the 
development of hypertension, and is therefore an early etiological factor in the elevation of 
blood pressure. These vascular changes are also subsequently stimulated and thus amplified 
by Ang II and the ROS, and also play a pertinent role in maintaining the hypertension. This 
confirms the notion that vascular remodelling is the hallmark of hypertension and has both an 
early and an amplifier role to play in the process. 
With these conclusions and recommendations for future studies this study has fortified the 
call for the use of antioxidant therapies in conjunction with currently administered medication 
in the treatment and management of essential hypertension. It has also provided justification 
for the call for the use of these therapies as a preventative measure in genetically susceptible 
individuals, due to the fact that the antioxidant intervention, targets more than just a single 
mechanism, and would thus aim to treat and attempt to address the multi-factorial nature of 
essential hypertension. The study has also provided evidence to the causative nature of Ang II 
in hypertension, and thus provided further reason for the use of Ang II antagonists and ACE 
inhibitors in the treatment and management of hypertension.  
The study has also demonstrated the significant role played by Ang II in the SHR, and shown 
Ang II to be a causative factor in this animal model of essential hypertension. The study has 
also highlighted the fact that there are many blood pressure elevating mechanisms that work 
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in parallel in the SHR and thus strengthens the validity of the use of this model in 
investigating the pathophysiology of essential hypertension. It has also demonstrated the 
intimate link between Ang II and oxidative stress in this model, and shown that the pathology 
of essential hypertension in this model is due in large part to the so called “Unholy Alliance”, 
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Appendix 1  - Sample of Blood Pressure Recordings 
 












Appendix  2 
Standard Curves 
Angiotensin II 
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